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Abstract
Class II UvrA is an ATP-binding cassette protein and a homolog of class I UvrA, the DNA
lesion detection component of the universal prokaryotic nucleotide excision repair system. We
show that Ecm16, a class II UvrA protein from Streptomyces lasalocidi, specifically recognizes
DNA duplex that contains the DNA bisintercalator antibiotic echinomycin. Heterologous
expression of Ecm16 in Escherichia coli renders host cells resistant to echinomycin. Interestingly,
Ecm16’s antibiotic resistance activity does not require the DNA repair proteins UvrA/B/C/D,
indicating that it operates independently of the cell’s nucleotide excision repair pathway. Unlike
UvrA, Ecm16 uses the insertion domain to regulate its ATPase activity dependent on the type of
substrate (damaged vs. undamaged DNA). We have determined the crystal structure of Ecm16 at
2.0 Å resolution. Although Ecm16’s structure is highly similar to that of UvrA, Ecm16 lacks the
UvrB-binding domain and its associated Zinc-binding module found in all UvrA proteins, and its
insertion domain appears to be mobile. We showed that Ecm16 can bind echinomycin independent
of DNA. Ecm16, when expressed in Brevibacillus system provides partial resistance against other
DNA bisintercalators like quinaldopeptin, thiocoraline and sandramycin. Our work has revealed
that Streptomyces lasalocidi has evolved a unique pathway to counter the assault of the DNA
bisintercalator antibiotic.
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Chapter 1: Introduction
1.1 BACKGROUND
Antibiotics are a blessing to human civilization for combating against infections or
microbes. The challenge of antibiotic resistance began soon after the discovery of the first
antibiotic. Antibiotic resistance is one of most serious global threats today. Each year, in United
States alone, at least 2 million infections and about 23,000 death are caused due to the antibiotic
resistant strains of bacteria.1,2 In Europe, about 25,000 people die each year due to multidrugresistant bacteria, which costs €1.5 billion annually to the European Union economy.3 Bacteria
utilize their genetic plasticity to resist the inhibitory action of antibiotics by gaining genetic
material, mutations, and changing the expression of their genome.4 The acquired antibiotic
resistance gene can be passed from one bacterium to another through division processes or by
horizontal gene transfer.5 After the initial use of the antibiotic, bacterial resistance to a given
antibiotic is developed and evolved withing an average of 50 years. Although the process of
antibiotic resistance occurs natural through genetic changes and is inevitably slow, humans have
augmented it through different anthropogenic activities.6,7 Antibiotic resistance has risen in both
gram-negative and gram-positive pathogens. Usually, the process of antibiotic resistance is slow,
occurring through genetic changes, overuse and misuse of antibiotics are the main drivers to
accelerate the process of antibiotic resistance. Various types of resistance mechanism evolved by
bacteria enable them to overcome the inhibitory actions of antibiotics. Understanding the
molecular aspects of these resistance mechanisms will provide strategic information towards the
development of novel therapeutic approaches against resistance.
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1.2 MECHANISMS OF ANTIMICROBIAL ACTION
To understand the mechanisms of resistance, it is important to recognize how various
antibacterial agent’s function. Vital functions in bacteria are specifically targeted by antibiotics.
Mechanisms of action of antimicrobial agents can be categorized as follows (Figure 1.1).
1. Interfering with cell wall synthesis: β-lactams (penicillin’s, cephalosporins, carbapenems,
and monobactams)8 and the glycopeptides (vancomycin and teicoplanin)9 class of
antibiotics hinder or prevent cross-linking of peptidoglycan in the cell wall synthesis
thereby making its structure unstable.
2. Protein synthesis inhibition: Antibiotics hinder the protein synthesis process by targeting
30S or 50S subunit of the 70S bacterial ribosome10. Macrolides, aminoglycosides, and
tetracycline’s class of antibiotics block protein synthesis by binding at 30S subunit, while
the chloramphenicol antibiotic can bind to the 50S ribosomal subunit.

Figure 1.1: Classification and mechanisms of antibiotic action on various target sites in bacteria.
(Adapted from Madigan and Martinko, 2006).
2

3. Nucleic Acid synthesis inhibition: Fluoroquinolones class of antibiotics inhibits DNA
gyrase and topoisomerase IV enzymes in gram-negative and gram-positive bacteria
respectively.11 These enzymes are crucial for the initiation of DNA replication.
4. Inhibition of metabolic pathways: The fact that the eukaryotic cells take the folate by an
active transport system and the microorganisms require their folate by de novo synthesis
pathway, has made the folate biosynthetic pathway a very good target for the antibiotics.
5. Osmotic imbalance of the bacterial membrane: Negatively charged peptidoglycan and
Lipopolysaccharides (LPS) of the bacterial outer membrane are the targets of the positively
charged polymyxins antibiotic molecules.12 These molecules interact with the cell
membrane, alter its structure thereby making it over permeable. These leads to osmotic
imbalance, outflow of various cellular metabolites and rapid intake of solvent thereby
causing cell death.
1.3 MECHANISMS OF ANTIBIOTIC RESISTANCE
The mechanisms of antimicrobial resistance fall into four categories: (1) active drug efflux
pumps; (2) target drug modification; (3) drug inactivation; (4) regulating drug uptake. There is
variation in the types of mechanisms utilized by gram-positive versus gram-negative bacteria.
Usually, gram-negative bacteria uses all four main mechanisms, whereas gram-positive bacteria
hardly uses regulating drug uptake mechanism and has less ability to utilize certain types of active
drug efflux pumps.13,14 Illustration of general resistance mechanism is shown in figure 1.2.
Resistance to antibiotics by dissemination of resistance genes occur through transformation,
transduction, and conjugation.

3

Figure 1.2: Mechanisms of antibiotic resistance in bacteria (Adapted from Gerard D Wright,
2010).
1.4 STRATEGY TO COMBAT ANTIBIOTIC RESISTANCE- LINKING SOIL TO THE CLINIC
Identifying the resistance genes in the disease-causing clinical pathogen can contribute to
combat the problem of antibiotic resistance. In 2009, Antibiotic Resistance Genes Database
(ARDB) contained about 13,293 genes that were resistant to various types of antibiotics.15
However, it has been hypothesized that the resistance genes found in clinical pathogens are
originated from the drug-producing organisms present in the environment.16 For example, it was
observed that the biochemical activity of aminoglycoside resistance enzymes encoded by
Streptomyces kanamyceticus was identical to those found in clinical isolates of Escherichia coli
and Pseudomonas aeruginosa.17 However, the resistance genes can undergo multiple rounds of
4

evolution during the process of gene transfer between environmental resistome and the clinic.
Another example of gene transfer event between environmental resistome and the clinic is the
presence of class-A extended-spectrum β-lactamase CTX-M gene originally found in
environmental Kluyvera spp. was present in clinical pathogens.18 Recently, Forsberg et al. using
metagenomic approach identified seven genes originated from non-pathogenic soil bacteria were
100% identity to resistance genes in clinical pathogens, including resistance against β-lactams,
tetracyclines, aminoglycosides, sulfonamides, and chloramphenicol.19 The amino acid
composition of aminoglycoside phosphotransferase APH (3’) enzyme between the clinical isolates
of

gram-negative

and

gram-positive

pathogens

and

environmental

Bacillus

circulans and Streptomyces fradiae bacteria is 100 % identical.20 The niche shared by the
environmental microbes and the pathogens is the most likely place for the transfer of resistant
genes. Identifying and mapping of the antibiotic resistance genes from the non-pathogenic
environmental microbes is a crucial step towards slowing the rise of clinical antibiotic resistant
pathogens.

1.4.1 Streptomyces soil bacteria is a pool of antibiotic resistance genes
Majority of the clinically approved antibiotics including streptomycin, tetracycline,
erythromycin, neomycin, gentamycin, etc are produced by a group of soil-dwelling gram-positive
filamentous bacteria, actinomycetes. About 70% of various clinically useful antibiotics for humans
are the produced by actinomycetes, mostly from genus Streptomyces as a secondary metabolite.
Streptomyces possess high guanine + cytosine (G+C) content in their genome and are distinguished
by their fungi like filamentous morphology. Understanding the self-resistance mechanism in the
antibiotic producing bacteria can contribute to bottleneck preventing transfer of environmental
genes to clinical pathogens. Two species of Streptomyces have been well studied: S. griseus which
5

is used for industrial production streptomycin antibiotic, and S. coelicolor, used for to perform
genetic studies. Most of the resistance genes found in Streptomyces are present in the same cluster
as the antibiotic biosynthesis gene.21 Most of the resistance genes are present on the stable plasmid
A and can be easily passed to another strain by conjugation.
1.4.2 Echinomycin is produced by Streptomyces lasalocidi
Nonribosomal peptides produced by Streptomyces are secondary metabolites, with diverse
biological functions including antimicrobial, antitumor, cytostatics, immunosuppressants,
pigments and antiviral activities.22-24 These peptides are not synthesized by ribosomal machinery,
but instead by large enzyme complex called nonribosomal peptide synthetase (NRPS) using a
thiol-templated mechanism.25 NPRSs are capable of synthesizing linear or cyclic peptides which
contain N-methylated, D-amino acids, and N-terminal attached fatty acids.26 27 NRPSs have been
found in all the three domains of life, but they are most prevalent in bacteria, and less frequent in
eukaryotes and archaea. Within the bacterial domain, NRPs are found with high frequency in
Proteobacteria, Actinobacteria, Firmicutes, and Cyanobacteria. There are reports about the
correlation between the number of NRPS’s clusters found and the genome size of the bacteria.28
NRPSs are usually encoded in a biosynthetic gene cluster found on a plasmid rather than the
chromosome.29 The nonribosomal peptide biosynthesis gene cluster typically contains one or more
regulatory genes as well as self-resistance genes to protect the host organism from the toxic
compounds they produce.
Echinomycin, which was originally isolated from Streptomyces echintus, is a cyclic
octadepsipeptide antibiotic, containing two quinoxaline rings that bisintercalate into double
stranded DNA.30 Echinomycin preferably binds to CpG steps in the DNA double helix and thereby
inhibits DNA replication and transcription.31 Structural studies have shown that the alanine
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residues in the echinomycin form hydrogen bonds with the guanine base in CpG and the two
central AT base pairs adopt Hogsten base pairing.32

33

The exocyclic 2-amino group of guanine

exposed in the minor groove of the DNA also contributes towards sequence-specific recognition
of DNA by echinomycin.34 35 The binding affinity of echinomycin for the DNA duplex is found to
be affected by the sequences flanking the CpG site.36
Table 1.1: Minimum Inhibitory Concentrations (MICs) of echinomycin against various humanassociated pathogenic bacteria.
Organism
Bacillus anthracis 40/BA 100
Bacillus anthracis 14578
Bacillus anthracis 28
Bacillus anthracis 62-8
Staphylococcus simulans ATCC 11631
Enterococcus faecalis ATCC 29212
Enterococcus faecalis VRE, ATCC 51299
Enterococcus faecium ATCC 49624
Listeria monocytogenes ATCC 19114
Listeria monocytogenes ATCC 19115
Shigella dysenteriae ATCC 11835
Staphylococcus epidermidis ATCC 12228
Staphylococcus aureus ATCC 29213
Staphylococcus aureus MRSA, ATCC 33591
Staphylococcus aureus GISA, ATCC 700787
Staphylococcus aureus ATCC 27734
Streptococcus pneumoniae ATCC 49619
Streptococcus pneumoniae ATCC 70674
Streptococcus pneumoniae ATCC 70676
Plasmodium falciparum

Echinomycin (µg ml-1)
1.4
1.99
2.4
1.4
0.25
0.125
0.125
<0.062
0.5
0.25
8.0
0.25
0.5
0.5
1.0
0.25
<0.0325
<0.0325
<0.0325
0.01

Echinomycin has been tested in phase I, II trial against various types of cancer.37 38 Besides
bisintercalation, echinomycin was observed to play role in apoptosis39, inhibition of cell
signaling40 and inhibition of hypoxia-inducible factor (HIF)-1α.41 Recent studies showed that the
nanoliposomal-echinomycin can be safe and effective therapeutic HIF-1α inhibition and can
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eliminate triple-negative breast cancer (TNBC).42 Echinomycin shows its antimicrobial activity
against various human associated pathogens43 (Table 1.1). The echinomycin resistant element
present in the Steptomyces can be transferred to these human-associated pathogens, which will
lead to loss of their activities. Therefore, understanding the echinomycin self-resistance
mechanism is crucial.
A 36-kb long echinomycin biosynthetic gene cluster was isolated from S. lasalocidi linear plasmid
(Table 1.2), which includes eight genes responsible for quinoxaline2-carboxylic (QC) acid (ecm2,
ecm3, ecm4, ecm8, ecm11, ecm12, ecm13 and ecm14) and five genes are involved in backbone
formation and modification (ecm1, ecm6, ecm7, ecm17 and ecm18).44 In the echinomycin
biosynthetic gene cluster, a putative gene ecm16 was identified. ecm16 overexpression in the
engineered echinomycin-producing strain led to a significant increase in antibiotic production.
Table 1.2: ORFs responsible for biosynthesis of the echinomycin antibiotic isolated from S.
lasalocidi.
ORF
ecm1
ecm2
ecm3
ecm4
ecm5
ecm6
ecm7
ecm8
ecm9
ecm10
ecm11
ecm12
ecm13
ecm14
ecm15
ecm16
ecm17
ecm18

Amino acids
527
248
362
472
n.a.
2,608
3,135
70
181
252
220
395
598
402
285
792
313
224

Putative function
QC activation
QC biosynthesis
QC biosynthesis
QC biosynthesis
Unknown
Peptide synthesis (modules 1-2)
Peptide synthesis (modules 3-4)
Unknown
Regulation
Regulation
QC biosynthesis
QC biosynthesis
QC biosynthesis
QC biosynthesis
Regulation
Self-resistance
Disulfide formation
Thioacetal formation
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1.5 RATIONALE BEHIND STUDY
DNA intercalators are promising antibacterial compounds. Out of all the resistance
mechanism studies till date, resistance mechanism of the DNA bis-intercalating drugs is not study.
While there is currently no clinical resistance against DNA intercalators as a general class, we
have found that certain soil actinobacteria are naturally resistant to intercalators. And since
environmental drug resistance elements are often mobile, emergence of DNA intercalator
resistance in human pathogens is a distinct possibility.45 By working in a model system to dissect
the DNA intercalator resistance mechanism, prior to the actual emergence of such resistance, we
will position ourselves ahead of the pathogens in the ongoing battle against drug resistance. The
goal of the study is to identify and characterize the self-resistance element present in the
echinomycin biosynthesis gene cluster. Understanding how cells interact with and respond to DNA
intercalators will enable development of novel treatment strategies and therapeutics. For example,
a molecule that inhibits the resistance mechanism could be developed and administered together
with conventional antibiotics to overcome drug resistance.
1.6 SPECIFIC AIMS OF THE STUDY
1. To investigate the role of putative gene ecm16 in the echinomycin biosynthesis gene cluster
2. Structural and biochemical characterization of S. lasalocidi Ecm16 protein
3. To understand the molecular mechanism of antibiotic resistance by Ecm16
4. To study the Ecm16’s substrate specificity towards its antibiotic resistance activity
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Chapter 2: To study the function of ecm16 in the echinomycin biosynthesis gene cluster
from S. lasalocidi
2.1 BACKGROUND
In the biosynthesis gene cluster of echinomycin antibiotic isolated from S. lasalocidi 46, the
role of ecm16 was unclear. To investigate its function, the ecm16 was recombinantly expressed in
E. coli host system. Functional studies of Ecm16 protein using disk-diffusion, growth curve assay
and in vivo phase contrast microscopy was performed to study the antibiotic resistance function of
Ecm16.
2.2 MATERIALS AND METHODS
2.2.2 Bacterial growth conditions
pBad-ecm16 was assembled using PCR amplified ecm16 with 3'-SacI and 5’-EcoRI
restriction sites/enzymes (Fast Digest, Thermo Scientific) and the digested plasmid was treated
with shrimp alkaline phosphatase (New England Biolabs). The ecm16 fragment was ligated (T4
DNA ligase, New England BioLabs) into pBad-My-His-A (Thermo Fisher Scientific) downstream
of araC, allowing for arabinose induction of ecm16. The resulting pBad-ecm16 plasmid was
confirmed with Illumina sequencing and used to transform K12 (Keio Collection parent strain)
using electroporation. Each K12 strain was also transformed with a pBad vector control with no
insert. Ampicillin was used to select positive transformations and confirmed using colony PCR.
2.2.3 Maximum growth in echinomycin
Maximum growth in echinomycin was determined by evaluating serial dilutions of
echinomycin in H2O when added to LB media inoculated with K12 E. coli culture, using 1 µM to
20 µM echinomycin. K12/pBad (vector control) and K12/pBad-ecm16 were grown overnight from
frozen stocks at 37°C and 200 rpm.
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2.2.4 Growth curves assay
Cultures were grown in liquid media with ampicillin overnight from frozen stocks,
incubated at 37°C and 200 rpm. Saturated culture was induced with a 0.2% arabinose solution for
30 minutes and used to inoculate 2 ml duplicate replicate samples at a starting optical density of
0.02 OD600 in 13 mm glass tubes. Cultures were grown in rich liquid media (LB), with ampicillin
and 0.2% arabinose, incubated at 37°C and 200 rpm. Optical density readings were taken every 30
minutes for 6 h using Thermo UV-Vis Spectrophotometer.
2.2.5 Microscopy
K12 strains were grown from frozen stocks and used to inoculate 3 ml of LB/Amp/0.2%
arabinose to 0.2 OD600. Cells were induced with 0.2% arabinose 30 minutes prior to dilution.
Following inoculation, cultures were treated with 5 µM echinomycin and grown for 5 hours.
Cultures were spotted on 0.2% agarose (Ultrapure, Invitrogen, Spain) discs, and visualized with
phase contrast microscopy using Zeiss Axio Observer 2.1 inverted microscope with a PlanApochromat 100×/1.40 Oil Ph3 M27 (WD=0.17 mm) objective, AxioCam 506 mono camera and
ZEN software. Cell size was calculated using ImageJ/FIJI with MicrobeJ. 47-50
2.3 RESULTS
2.3.1 Expression of ecm16 provides resistance against echinomycin
To determine whether Ecm16 display a protective function against echinomycin toxicity,
we used E. coli (K12 parental strain from Keio collection BW25113, referred here as K12) cells
as a heterologous host system to express ecm16. The natively echinomycin-sensitive E. coli cells
were transformed with a low-copy vector encoding ecm16 under the arabinose inducible promoter
(pBAD-ecm16). In the absence of echinomycin, E. coli cells with vector-control-only (VCO)
reached saturation (OD600nm ~1.0) within a 6 h growth period (Figure 2.1). The same VCO cells
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grown in the presence of 1 µM echinomycin only reached ~0.35 OD600nm within the same 6 h
period. Almost no detectable growth was observed for VCO cells at echinomycin concentration of
10 µM or higher. In contrast, E. coli cells expressing ecm16 reached equivalent maximal densities
when grown in the presence or in the absence of supplemented echinomycin. Using growth curve
analyses, we determined the effect of ecm16 expression on doubling rates (Figure 2.1). In the
absence of echinomycin, E. coli with or without expression of ecm16 were able to double every
~0.68 h under our experimental conditions. However, in the presence of echinomycin, the doubling
rate of VCO cells increased more than 7-fold. Remarkably, cells expressing ecm16 were able to
maintain their normal doubling rate even at the highest concentration of echinomycin tested (20
µM). Furthermore, we tested the ability of Ecm16 to prevent cellular filamentation that results
from exposure to echinomycin. E. coli adopt filamentous shapes in response to a variety of stressful
environments, including DNA damage and exposure to antibiotics.51-54 The average cell length of
E. coli was determined to be ~2.5 µm when grown in the absence of any drug. However, the
average cell length increased six-fold (~14.9 µm) when grown in the presence of echinomycin (5
µM) (Figure 2.1d). Exposure to echinomycin resulted in cells with broad cell length distribution
and maximum lengths reaching up to ~54 µm. We observed that the expression of ecm16 alone in
the absence of any echinomycin, resulted in an average cell length that was longer (~3.8 µm)
compared to the VCO (~2.5 µm). However, when echinomycin was supplemented to cells
expressing ecm16, the cell length was not altered compared to the no echinomycin control
treatment. In summary, our in vivo analyses revealed that the expression of ecm16 in E. coli cells
results in protection against the toxicity caused by echinomycin exposure.
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Figure 2.1: Expression of ecm16 gives resistance against echinomycin. a, Structure of
echinomycin. b, Optical density after 6 hours. Exposure to echinomycin results in reduction of E.
coli growth in liquid media. Maximum optical densities were determined after 6 h exposure to
increasing echinomycin concentrations. Echinomycin was added at time zero to cultures at 0.2
OD600 nm. E. coli K12 strains with pBAD vector-control-only (VCO) or pBAD-ecm16 (p(ecm16)
were used for comparison. Error bars represent standard deviation for duplicate replicates of one
trial, analysis is representative of three independent trials. c, Exponential state growth curves of
K12/pVCO and K12/p(ecm16) on a semi-logarithmic plot. Cultures were grown in rich media (LB)
supplemented with echinomycin (0 to 20 µM) and arabinose inducer (0.2 %). Error bars represent
standard error of the mean (SEM) of duplicate replicates. All results shown are representative of
three independent replicates. d, Phase contrast microscopy of strains K12/p(VCO) (top panels) and
K12/p(ecm16) (bottom panels) grown in the presence of inducer (arabinose 0.2 %) supplemented
with or without 5 µM echinomycin (ech). Cells were grown in the presence of echinomycin for 5
h and subsequently spotted on 1 % agarose minimal media pads for imaging. Scale bar = 10 µm.
Cell size distribution and average cell length and standard deviation for 100 cells per condition are
shown. 7% of cells displayed cell lengths over 25 µm (not included in plot). Cell lengths were
measured using the software MicrobeJ. Representative of three independent replicates are plotted.
Cell lengths were binned in 0.5 µm increments and plotted using Prism.
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Chapter 3: Structural determination of Ecm16
3.1 BACKGROUND
Since one of our aims was to understand how Ecm16 protects cells against the cytotoxic
effects of echinomycin antibiotic, we propose that the three-dimensional structure of Ecm16 can
provide the mechanistic insights related to resistance mechanism. The amino acid composition of
Ecm16 suggest the protein has conserved nucleotide interacting Walker A and Walker B motifs
like other ABC ATPase. This chapter discuss the structural aspects of Ecm16.
3.2 INTRODUCTION TO X-RAY CRYSTALLOGRAPHY
The three-dimensional structure of protein molecules is determined using three major
techniques NMR, X-ray crystallography and Cryo-Electron microscopy. Each technique has its
own advantages and limitations i.e., for NMR and Cryo-EM protein size should be smaller than
20 kDa and higher than 200 kDa, respectively. Therefore, in our case, X-ray crystallography would
be best approach to get structural information of Ecm16. One of the requirements in X-ray
crystallography is that we need a protein sample of high purity and homogeneity. Structure
determination using recombinant proteins consists of several steps – cloning of the desired gene,
its overexpression, purification of the protein, crystallization, collection of diffraction data from
the crystals and finally phase determination, and cycles of model building and refinement.
3.2.1 Principle of crystallography
The basic concept of crystallization is separation of protein molecules from solution. This
can be achieved by adding compounds that aid in the segregation of protein molecules out of the
solvent. Various parameters like pH, buffer, temperature, salts, protein concentration, affect the
crystallization process. The quality of crystals is an important factor in deciding the resolution of
diffraction.
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For the protein molecules to crystallize and favor nucleation process, ∆G should be
negative. In the Gibbs-Helmholtz equation, this change in the Gibbs-free energy, ∆G at constant
temperature is dependent on entropy, ∆S and enthalpy, ∆H (equation 1). At equilibrium, the
crystallization constant associated with the Gibbs-free energy is shown in equation 2, at which T
is the absolute temperature and R is the gas constant. The process of crystallization is entropydriven and is favored with the increase in the entropy.55 The water molecules which are surrounded
as well as confined within protein molecules contribute to the overall increase of the entropy.
Based on this, the modified equation for the crystallization is shown in equation 3.56
ΔGcryst = ΔHcryst - TΔScryst …………………………............................1
Kcryst = exp (-ΔG˚cryst / RT) …….…………………............................. 2
ΔH˚cryst = ΔH˚cryst – T (ΔS˚protein + ΔS˚solvent) cryst ……………………3
After the crystallization setup, the protein molecules can decide three different paths of
precipitation, metastable zone, and nucleation. As shown in the Oswald-Miers diagram, crystals
are formed in the supersaturation state 57 (Figure 3.1). Nucleation is described as the phenomenon,
where the protein after reaching the supersaturation state, starts coming out of solution in the form
of crystal.57 Nucleation can be controlled by seeding techniques like micro-seeding and macroseeding. In micro-seeding method, solution from the drop is transferred to the new crystallization
drop while in the case of macro-seeding, the small crystals are transferred to the new fresh drop to
drive the crystallization process.
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Figure 3.1: Oswald-Miers phase diagram.
3.2.2 Methods of crystallization
Vapor diffusion, batch crystallization, free-interface diffusion and dialysis are few of the
various methods of protein crystallization. The most common method of crystallization is the
vapour diffusion.55 In this method, the droplet contains the mixture of the protein and
crystallization solution and is set to exchange with the crystallization solution containing large
reservoir. The droplet containing the mixture of protein and the crystallization solution has lower
concentration of salts and precipitant. Over course of time, vapor diffusion takes place between
the droplet and the reservoir, which continues until equilibrium is reached. This gradual changes
in the protein concentration and the precipitant leads to supersaturation resulting in nucleation and
crystal growth.
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3.2.3 Crystal to structure determination
During the crystal diffraction using X-ray, the data is recorded as intensities which are an
estimate of the structure factor amplitudes with unique h,k and l values. Electron density function
is denoted as all the electrons on the molecules of the crystal structure. The electron density
function is related to the phase and the amplitude of the diffracted wave through a Fourier
transform. The protein structure is derived in real space from the reciprocal lattice using inverse
Fourier transform. Electron density calculation requires the information about both amplitude and
phase of the structure factors. Amplitudes can be attained from the intensity values, but phase
information can be achieved using Molecular Replacement (MR), Single isomorphous
replacement/Multiple isomorphous replacement (SIR/MIR), Single wavelength anomalous
diffraction/multi-wavelength anomalous diffraction (SAD/MAD) X-ray crystallography methods.
58

Figure 3.2: Workflow for protein structure determination using X-ray crystallography.
3.2.4 Indicators of crystallographic data
In X-ray crystallography, the measure data is the intensities of reflections, which produce
structure factor amplitudes having h, k, and l indices defined as lattice planes. The standard
indicator for assessing the agreement of a refined model with the data is the
crystallographic R value, defined as shown in equation 4.
𝑅 = ∑hkl|Fobs(hkl) − Fcalc(hkl)|/ ∑hklFobs(hkl) .........................................................4
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where Fobs(hkl) and Fcalc(hkl) are the observed and calculated structure factor amplitudes,
respectively. R is 0.0 for perfect agreement with the data, and R is near 0.59 for a random model59.
Since, the R factor can be made arbitrarily low for models having sufficient parameters to
overfit the data, Rfree as a cross-validated R based on a small subset of reflections not used during
refinement60. The R for the larger “working” set of reflections is then referred to as Rwork. The Rfree
and Rwork for the Ecm16 crystal data is 0.23 and 0.21 respectively (Table 3.1). The crystallographic
data quality can also be assessed analogous indicator Rmerge which measures the spread
of n independent measurements of the intensity of a reflection, Ii(hkl), around their
average, I(hkl)I(hkl). In crystallography, indicators to describe aggregated properties of the data
are necessary as the number of reflections are hugh that it is prohibitive to inspect individual
reflections. The availability of multiple observations (called “multiplicity” or “redundancy”)
allows their precision to be measured. Data are typically truncated at a resolution before
the Rmerge (or Rmeas) value exceeds ~0.6 to 0.8 and before the empirical signal-to-noise
ratio, ⟨I/σ(I)⟩〈I/σ(I)〉, drops below ~2.061. The latest, statistically justifiable and so far most useful
addition to the crystallographic data precision indicators is CC1/2, which is derived from
mainstream statistics and measures the correlation coefficient between merged intensities obtained
from two random subsets of the data62. Furthermore, from CC1/2 we can calculate CC*, a quantity
on the same scale as correlation coefficients between measured intensities and Fcalc2 that are
obtained from a model63.
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3.3 MATERIALS AND METHODS
3.3.1 Expression and purification of Ecm16
The codon-optimized construct of S. lasalocidi ecm16 gene in pUC18-mini vector for E.
coli was purchased from GenScript.com. The ecm16 gene was subcloned into a pET-28a (+)
expression vector (Novagen, cat# 69864-3) between the restriction enzyme sites NdeI and EcoRI
at the 5’ and 3’ end respectively. The ecm16-pET28a (+) construct was transformed into E. coli
strain BL21-DE3 and plated on an LB agar plate supplemented with 50 µg/ml kanamycin
antibiotic. 2-3 colonies from the plate were inoculated in 5 or 10 ml LB broth containing 50 µg/ml
kanamycin and culture was grown overnight at 37˚C and 200 rpm. When the OD600 reached at
optimum expression level (0.6-0.8), the cells were induced using 0.5 mM IPTG and the
temperature was shifted to 18˚C of the shaker-incubator. Recombinant Ecm16 protein was
expressed by transforming E. coli BL21 (DE3) (Novagen, Merck Millipore) host strains with the
recombinant pET28a constructs encoding Ecm16 wild type. Cells were cultured at 37°C in 5 ml
of LB medium supplemented with kanamycin to an optical density of ~0.6-0.8 at 600 nm. Protein
expression was performed by inducing the cells with 0.1 mM IPTG, and growth was continued for
a further 16 h at 18°C. and 200 rpm. Cell pellet was resuspended in lysis buffer containing 50 mM
HEPES (pH 7.5), 200 mM NaCl, 10% glycerol, 10 mM Imidazole, 1 mM Phenylmethylsulphonyl
fluoride (PMSF), 10 µg/ml DNase and 10 mM MgCl2. Cells were disrupted using sonication
(Branson Ultrasonics) and cell debris was discarded by centrifugation at 15,000 g for 45 minutes
at 4 °C. Cleared cell lysate was applied on 5 ml His-Trap Crude column (GE Healthcare)
equilibrated with loading buffer (50 mM HEPES, pH, 7.5 and 200 mM NaCl). The protein was
eluted with a step gradient of imidazole (250 mM) using elution buffer (50 mM HEPES pH 7.5,
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200 mM NaCl, 500 mM Imidazole). Ecm16 eluted from the nickel column was diluted up to 10fold using dilution buffer (50 mM HEPES pH 7.5, 50 mM NaCl). The diluted protein was applied
to 5 ml Hi-Trap Q HP anion-exchange column (GE Healthcare). Protein was eluted with 5 column
volumes (CV) linear NaCl gradient from 50 mM to 500 mM concentration. The protein was
concentrated up to 4-6 mg ml-1 and gel filtration was performed on Superdex 200 10/300 GL (GE
Healthcare) equilibrated with storage buffer (50 mM HEPES pH 7.5, 50 mM NaCl). The eluted
protein sample was concentrated up to 8-10 mg/ml, shock-frozen in liquid nitrogen and stored at 80°C.
3.3.2 Secondary structure analysis of Ecm16
The far-UV spectra (200-260 nm) of the purified Ecm16 at a concentration of 1 mg/ml was
recorded at 25 °C, in 1-mm path length cell, using a JASCO J-815 (Japan) spectropolarimeter. A
buffer (50 mM HEPES pH 7.5, 50 mM NaCl) sample without protein was subtracted from the
spectra to get rid of any background signal.
3.3.3 Determination of the oligomeric state of the Ecm16
High Molecular Weight (HMW) marker kit (GE, Healthcare) was used to determine the
oligomeric state of the Ecm16. Stock solutions of biomolecules Ovalbumin (Mr 43 000),
Conalbumin (Mr 75 000), Aldolase (Mr 158 000), Ferritin (Mr 440 000), were prepared in storage
buffer (50 mM HEPES pH 7.5, 50 mM NaCl). This mixture was applied to the size exclusion
column (Superdex 200, 10/300 GL GE healthcare). The elution volume (Ve) for each of the
standard proteins was obtained by measuring the volume of the eluent from the point of injection
to the center of the elution peak from the UV curve. The void fraction (Vo) of the column was
determined by loading Blue Dextran 2000, (Mr 2000) separately at 1 mg/ml concentration. Purified
Ecm16 protein was loaded onto the column and the elution volume was calculated. Kav values for

20

each of the standard protein were calculated. A calibration curve of Kav versus log molecular
weight of the marker proteins was plotted. The oligomeric molecular weight of Ecm16 was
obtained from the calibration curve, corresponding to the Kav value obtained.
3.3.4 HPLC analysis of purified Ecm16
Heat extraction method was used to denature purified Ecm16 protein and release the
nucleotide bound. Purified Ecm16 protein samples at 50 µM concentration were heated at 65 °C
for 20 minutes using Thermomixer C (Eppendorf), resulting in denaturation and release of
associated nucleotides. After heat treatment, denatured or precipitated Ecm16 was pelleted by
centrifugation at 12,000 g for 30 minutes at room temperature using Centrifuge 5424R
(Eppendorf). The supernatant containing the released nucleotide was removed and filtered through
0.22 µm PES membrane syringe filter (Millipore Sigma). ATP, ADP and AMPPNP (50 µM)
nucleotide standards were treated under same experimental conditions as the Ecm16 protein
samples. HLPC analysis of the standard nucleotides and the Ecm16-extracted nucleotide was
carried out on a 1260/1290 Infinity HPLC system (Agilent Technology) using 5 µM C18 reversephase analytical column (150 X 4.6 mm). 20 µl of samples was injected in the mobile phase (50%
Acetonitrile and 50 % methanol) at the 1 ml/min flowrate for 20 minutes. The absorbance at 254
nm, was plotted against retention time.
3.3.5 Crystallization of Ecm16
Around 900 conditions from commercially available screens (Molecular dimensions,
Hampton Research) were screened using NT8 (Formulatrix) crystallization robotic system. The
drop size of 200 nl protein (3 and 5 mg/ml) and 200 nl of the crystallization condition was set in
96-well sitting drop plates (ARI, Intelli). Initial hit obtained was reproduced and optimized to
obtain well-diffracting crystals. Optimal crystals of Ecm16 were grown at 18°C by vapour
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diffusion using hanging drop, by mixing 1 µl of Ecm16 (8 mg/ml) containing 10 mM MgCl2 and
1 mM ADP with 1 µl of equilibration buffer (0.1 M MES pH 6.5, 0.2 M sodium thiocyanate and
12 % PEG (w/v) 20K. For cryoprotection, crystals were transferred into the same buffer including
20% v/v ethylene glycol before flash-freezing. Desalting-purified oligonucleotides of 32bp length
were purchased from Integrated DNA Technologies. The oligonucleotides possess single
echinomycin binding site (5’ ACGT 3’) at the center. Before crystallization, oligonucleotide was
mixed with echinomycin at molar ratio of 1: 1.1 DNA/Echinomycin and incubated for 15 minutes
at room temperature. Further, purified Ecm16 was added to the echinomycin-DNA mixture at the
molar ratio of 1.2: 1 DNA/Ecm16 dimer and incubated for 30 minutes at 4°C. The final
concentration of Ecm16 was 5 mg/ml. The complexes were mixed with an equal volume with the
crystallization conditions and crystallized by sitting-drop vapor diffusion at 18 °C using
Formulatrix crystallization robotic system. The initial crystals grown using 32-mer palindromic
dsDNA, but they did not diffract X-rays, so we carried out systematic optimization of the length
of the oligonucleotides and the position of echinomycin binding site. Crystals containing 28 bp
DNA were at 18°C by vapour diffusion using hanging drop, by mixing 1 µl of Echinomycin-DNAEcm16 complex with 1 µl of equilibration buffer containing 0.2 M Ammonium Sulphate, 0.1 M
HEPES pH 7.5, 25 % PEG 3350. Crystals containing 22 bp DNA
3.3.6 Structure determination
X-ray diffraction data was collected at Advanced Photon Source, Argonne National
Laboratory at wavelength of 1 Å on beamline 17-ID-B and processed using autoPROC program.64
A search model of UvrA2 structure (PDB: 2VF7)65 that included parts of ATP-binding I and
signature II was used for molecular replacement using PHASER of CCP4 program66. The initial
model was traced using the resulting electron density map after molecular replacement followed
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by crystallographic refinement using program PHENIX and REFMAC 67. The model building was
performed using COOT68 with alternated sessions of refinement using PHENIX69. The final model
consists of 15-81/88-110/113-148/172-181/294-598/608-792 chain A, 15-78/89-151/173184/296-599/608-792 chain B, 4 ADP molecules, 2 Mg2+ ions, 4 Zn

2+

ions and 678 water

molecules. PYMOL70 was used to perform structure analysis and preparing illustration.
3.3.7 Sequence alignment
Multiple sequence alignment of S. lasalocidi Ecm16, S. nogalator SnorO, S. peuceticus
DrrC, X. axonopodis UvrA2, D. radiodurans UvrA2, P. putida UvrA2, B. stearothermophilus
UvrA, E. coli UvrA, M. tuberculosis UvrA and T. maritima was performed using ClustalW 71 and
the alignment figure was generated using the ESpript 3.0 program.72
3.4 RESULTS
3.4.1 Expression and purification of Ecm16
ecm16 gene

was

cloned

into the pET-28a(+)

expression

vector using

the NdeI and EcoRI restriction sites at 5’ and 3’ end of the gene respectively. A highintensity coomassie stained band corresponding to ~ 86 kDa molecular size on SDS-PAGE in
IPTG induced sample confirmed the over-expression of the ecm16 gene (Figure 3.3a). In the lysis
buffer, small amount (10 mM) of imidazole was added to prevent non-specific binding of the
endogenous proteins in the cell lysate that have histidine clusters. In the nickel-affinity
chromatography step of purification, the N-terminal His-tag of the Ecm16 protein was bound to
the nitrilotriacetic acid (NTA)-agarose resin of the column. This was confirmed by analyzing the
flow-through sample in the SDS-PAGE gel (Figure 3.1a). Ecm16 was eluted using step gradient
at 250 mM imidazole concentration. In the anion exchange chromatography step, we observed
that addition of DNase enzyme to the cell lysate shifts the NaCl concentration at which Ecm16 is
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eluted. Ecm16 elutes approximately at 280 mM (conductivity = 23.7 ms/cm) and 740 mM NaCl
(conductivity = 58.2 ms/cm) concentration with and without addition of DNase enzyme
respectively. This indicates that Ecm16 is a DNA binding protein and the two different peaks in
the AEC is due to non-specific binding of DNA from the cell lysate. Our size-exclusion
chromatography result indicates that Ecm16 forms a homodimer in solution.
Overall, the preparation of His-tagged Ecm16 protein with higher purity (> 90 %) was successfully
achieved

by

employing

chromatography and size

a

combination

of affinity

chromatography, anion

exclusion chromatography (Figure

3.3a). Approximately,

exchange
2

mg

of Ecm16 could be obtained from one liter of LB culture. Purified protein was flash frozen in
liquid N2 and stored at -80°C until needed.

Figure 3.3: a, SDS-PAGE analysis of purified Ecm16 using various chromatographic methods. b,
Size-exclusion chromatography elution profile of Ecm16 (red) and calibration curve.
Experimentally determined Ecm16 molecular weight is 177.5 kDa, and the theoretical molecular
weight of the Ecm16 homodimer is 172.6 kDa.
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3.4.2 Ecm16 forms homodimer in solution
The molecular weight of Ecm16 was determined by comparing its elution volume
parameter (Kav), with that of known standard proteins using size exclusion chromatography.
Column void volume of 8.64 ml was obtained by running blue dextran protein at 1 mg/ml
concentration separately. At 2.5 mg/ml concentration, Ecm16 appeared as a single peak with 12.2
ml retention volume. Since, Ecm16 monomer is 86.01 kDa, the calculated molecular weight agrees
with the theoretical molecular weight of the dimer, which includes an N-terminal His-tag
(Figure 3.3b). To study the effect of nucleotide binding and hydrolysis on the oligomeric state, the
protein was incubated with 100-fold excess of ATP, ADP and AMP-PNP (non-hydrolysable
analog

of

ATP)

nucleotides and MgCl2.

However,

the

protein

eluted

at

the same

retention volume, suggesting dimerization of Ecm16 is nucleotide independent.
3.3.3 Ecm16 adopts predominantly α-helical structure
Secondary structure analysis of Ecm16 was performed using circular dichroism
spectroscopy. One positive band and two negative bands corresponding to 205 nm and 215, 222
nm indicated a characteristic of an ordered α-helical structure (Figure 3.4a). The CD spectroscopy
analysis confirms the α-helical secondary structural conformation of the Ecm16.
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3.3.4 Purified Ecm16 is in the ADP nucleotide bound form
An HPLC analysis was carried out to characterize the nucleotide bound to the purified
Ecm16. This analysis method can distinguish ADP and ATP nucleotides clearly due to the different
rention times. The HPLC profile of Ecm16 suggests the protein is 100 % bound to ADP nucleotide
(Figure 3.4b)

Figure 3.4: a, Circular dichroism spectrum of Ecm16. b, HPLC analysis of nucleotide release
from Ecm16 expressed in E. coli. ATP (25 µM) and ADP (25 µM) dissolved in 50 mM HEPES
pH 7.5, 50 mM NaCl were used as standards. All solutions were heated to 65 °C and incubated
for 30 minutes prior to analysis.

Figure 3.5: Polygonal shaped crystals of Ecm16.
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3.3.5 Crystal structure of Ecm16

The polygonal shaped crystals of Ecm16 appeared within three days and grew to
full size (ranging from 30 µm to 100 µm) in one week (Figure 3.5). The crystals were
soaked in a cryo buffer containing 20% glycerol and were immediately flash frozen by
plunging it in liquid nitrogen.
The structure of Ecm16 at 2.0 Å resolution was determined using the molecular replacement
method. The final model consists of the Ecm16 homodimer, four adenosine diphosphate (ADP)
molecules, two Mg2+ ions, four Zn2+ ions, 676 water molecules, and has a Rwork and Rfree of 0.21
and 0.23, respectively (Table 3.1). Regions in Ecm16 that have ambiguous electron density were
not modelled (Table 3.2). The most prominent missing sections are chain A residues 182-293 and
chain B residues 185-295 that encompass the entire insertion domain. This is consistent with the
observation that the insertion domain in the homologous class I UvrA proteins is highly flexible.
Electron density at the proximal and distal nucleotide-binding sites clearly show presence of ADP,
and not ATP, at both sites (Figure 3.7).
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Figure 3.6: Crystal structure of Ecm16. a, Overall structure of the Ecm16 homodimer. Domains are colored
coded as indicated in the bar graph at the top. Atoms of ADP are drawn as spheres. Zn2+ and Mg2+ ions are
represented as grey and green spheres, respectively. b, Proximal nucleotide-binding site. c, Distal
nucleotide-binding site. d, Zinc-binding sites.
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Figure 3.7: a, Proximal and b, distal nucleotide-binding site of Ecm16. ADP is shown in stick
representation and Mg2+ ion in the proximal site is shown as a green sphere. Composite omit map
of ADP and Mg2+ contoured at 2.5 σ.
Identity of the Ecm16-bound nucleotide was further confirmed using liquid
chromatography analysis. Mg2+ ion is observed only at the proximal nucleotide binding site, and
not at the distal site, even though we crystallized Ecm16 in the presence of 10 mM MgCl2. Ecm16
forms a head-to-head homodimer, and each protomer contains two ABC ATPase motifs, termed
nucleotide-binding domain I and II (NBD-I and NBD-II) (Figure 3.6a). NBD-I consists of the
ATP-binding I, signature I and insertion domain. In our crystal structure, the insertion domain is
not visible, most likely due to its flexibility. NBD-II consists of ATP-binding II and signature II
domains. Ecm16’s two NBDs have a similar structure (R.m.s.d. = 1.5 Å for 208 Cα atoms), but
NBD-II has a 31-residue deletion, corresponding to residues 66-99 of NBD-I (Figure 3.8a). This
feature is not found in previously reported UvrA or UvrA2 crystal structures. The functional
significance of this deletion is unknown. The ATP-binding domains contain the Walker A, Walker
B motifs and the α-helical ABC signature subdomain containing the LSGGQ sequence that are
observed in ABC transporters73 and DNA repair proteins.74 The ATP-binding and signature
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Table 3.1: Data collection and refinement statistics.
Ecm16
Data Collection
Beamline
Processing software
Wavelength (Å)
Resolution range (Å)
Space group
Unit Cell a, b, c (Å)
Unit Cell α, β, γ (°)
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/sigma(I)
Wilson B-factor
R-meas
CC1/2

APS 17-ID-B
XDS
1.0
173.61-2.07 (2.04-2.04)
P3121
141.1 141.1 173.6
90 90 120
2,592,606 (129,966)
127,062 (6,279)
20.4 (20.7)
99.96 (99.99)
23.54 (2.30)
38.46
0.09 (1.56)
1 (0.79)

Refinement
Refinement reflections
R-free reflections
R-work
R-free
No. of atoms
macromolecules
Ligands
Solvent
Protein residues
RMS (bonds)
RMS (angles)
Ramachandran favored (%)
Ramachandran allowed (%)
Ramachandran outliers (%)
Rotamer outliers (%)
Clash score
Average B-factor (Å2)
macromolecules
ligands
solvent
Number of TLS groups
Highest-resolution shell statistics are in parentheses.
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126,877 (12,542)
6,146 (589)
0.21 (0.29)
0.23 (0.33)
10,081
9,291
114
676
1254
0.008
1.02
96.92
2.92
0.16
2.63
5.69
46.90
47.09
37.65
45.86
2

Table 3.2: List of unmodelled residues in the Ecm16 crystal structure.
Chain

Residue

Region

A

1-14

ATP-binding I

A

82-87

ATP-binding I

A

111-112

Signature I

A

149-171

Signature I

A

182-293

Signature I and insertion

A

599-607

Signature II

B

1-14

ATP-binding I

B

79-88

ATP-binding I

B

152-172

Signature I

B

185-295

Signature I and insertion

B

600-607

Signature II

domain is connected by the Q-loop. The locations of various motifs and secondary structure
elements of Ecm16 in the primary sequence are provided in figure 3.17. Each Ecm16 protomer is
a tandem ATPase. It contains two composite nucleotide-binding sites, each formed at the interface
between the two NBDs (Figure 3.6a). The proximal nucleotide-binding site is sandwiched between
ATP-binding domain I and signature domain II, and the distal nucleotide-binding site is
sandwiched between ATP-binding domain II and signature domain I. The phosphate groups of
ADP participate in an extensive hydrogen interactions with Ecm16 (Figure 3.6b and c). Each
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Ecm16 protomer also contains two zinc-binding modules; first module consists of C176, C179,
S297, and C299, and the second module consists of C589, C592, C612, and C615 (Figure 3.6d).
These zinc-binding modules correspond to zinc-binding module 2 and 3 of UvrA. Zinc-binding
module 1 found in UvrA proteins is not present in Ecm16. The dimer interface of Ecm16 buries
~3,900 Å2 of surface area and is comprised of residues from the ATP-binding I, signature I and
signature II domains (Figure 3.8b).

Figure 3.8: a, Comparison of NBD-I (white) and NBD-II (grey) of Ecm16. The α-helix and βsheet segments highlighted in red are present in NBD-I but they are absent in NBD-II. b, The dimer
interface of Ecm16 consists of 30 residues from ATP-binding I (yellow), 12 residues from
signature I (green) and two residues from signature II (blue).
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The ventral side of Ecm16 features a long groove that is lined with numerous basic residues
(R136, K142, K381, K384, R567, K568, R537, K549, K572 and K577) (Figure 3.9). This ~10 nm
long and ~2 nm wide groove can potentially accommodate a ~32 bp B-form DNA.

Figure 3.9: Electrostatic surface potential representation of Ecm16 (red = negative, blue =
positive, white = neutral). The DNA helix is illustrated as an orange cylinder.
3.3.6 The structure of Ecm16 resembles UvrA protein from NER pathway
The overall structure of Ecm16 closely resembles that of UvrA from B. stearothermophilus
(R.m.s.d. = 2.6 Å for 1,002 Cα atoms) which is the first of the four proteins of the Nucleotide
Excision Repair (NER) pathway in prokaryotes (Figure 3.10). The NER pathway although shows
wide spectrum for its DNA repair activity, it is mainly devoted to repair bulky DNA damages like
UV lesions or benzo[a]pyrene adducts. The NER process is highly conserved in both prokaryotes
and eukaryotes. DNA damage recognition and cleavage by the NER UvrABC proteins is a
multistep ATP dependent process. UvrA forms homodimer in the solution in an ATP dependent
manner.75 UvrA interacts with UvrB either as UvrA2B76 or UvrA2UvrB277 complex. UvrA is
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involved in DNA scanning and damage recognition. UvrA recruits UvrB, which separates the two
strands and recruits UvrC, an endonuclease, to the lesion site which cleaves the phosphodiester

Figure 3.10: Crystal structure of Ecm16 (PDB ID: 3SH1) from Streptomyces lasalocidi, UvrA
(PDB ID: 2R6F) from Bacillus stearothermophilus. Each monomer is labelled as dark and light
grey. Nucleotides are shown as ball and stick model and the zinc ions are represented as orange
sphere.

bond eight nucleotides upstream and up to five nucleotides downstream of the modified nucleotide.
Next, UvrC recruits UvrD, which displaces the cleaved DNA fragment. Finally, DNA polymerase
I synthesizes the missing stretch of DNA using the undamaged complementary strand and DNA
ligase seals the breaks, thus completing the repair (Figure 3.11).
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Figure 3.11: Schematic overview of the prokaryotic nucleotide excision repair pathway, leading
from damage recognition to damage verification to damage removal and resynthesis.
DNA lesions repaired by NER include pyrimidine dimers78,79, unpaired T and G residues80,
backbone modifications such as single nucleotide gaps and nicks81-84, and adducts of anthramycin
81,85,86

, cholesterol87, fluorescein84, and polypeptides.88 The unusually broad substrate specificity

of NER is attributable to UvrA, the damage sensor component of NER. Ecm16, like UvrA2, does
not have the UvrB-binding domain and the associated Zn-binding module 1 which are present in
all class I UvrA proteins. Otherwise, the three-dimensional structure of Ecm16, UvrA, and UvrA2
are highly homologous, which suggests that these proteins employ a similar DNA-substrate
recognition and binding mechanism. The crystal structure of Thermotoga maritima UvrA bound
to a damaged 32 bp DNA has previously revealed that the DNA contacting residues in UvrA come
from the signature II domain, located at both ends of the DNA-binding groove.89 Furthermore,
these residues only interact with the DNA backbone, and away from the damage-containing site.
Majority of these DNA-interacting residues are structurally conserved in Ecm16 (Figure 3.12).
Therefore, we predict Ecm16 to bind the DNA substrate in a manner like UvrA.
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Figure 3.12: Superposition of the DNA contacting region in Thermotoga maritima UvrA (blue,
PDB ID: 3PIH) and Ecm16 (blue). Residues in UvrA that contact the DNA are highlighted in
yellow.
3.3.7 Ecm16 is an Steptomyces class II UvrA protein
The UvrA proteins are divided into five classes based on the analysis of the homologous
proteins present in various bacterial species.90 Most of the bacteria except for species belonging to
Chlamydiae phylum consists of class I UvrA homolog. Class II UvrA proteins has a deletion of
residues belonging to insertion domain and the first zinc-finger C motif. Ecm16, lacking both the
insertion domain and the C motif components is a class II UvrA homolog (Figure 3.13 and 3.15).
The polypeptide sequence of Ecm16 is highly identical (~ 51-65 %) to other Streptomyces class II
UvrA proteins compared to the class I homologs (~ 39-43%) from E. coli, B. stearothermophilus,
M. tuberculosis and T. maritima (Table 8.3). The nucleotide interacting Walker A, Walker B,
Signature sequence and the Q-loop regions are strictly conserved, and the insertion domain is the
most variable region (Figure 3.15).
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Figure 3.13: Crystal structure of Ecm16 (PDB ID: 3SH1) from Streptomyces lasalocidi, and
UvrA2 (PDB ID: 2VF*) from Deinococcus radiodurans. Each monomer is labelled as dark and
light grey. Nucleotides are shown as ball and stick model and the zinc ions are represented as
orange sphere.
The sequence alignment of UvrA2 and Streptomyces class II proteins was generated using
ClustalW to generate phylogenetic tree (Figure 3.14). The loci segregated into three main
evolutionary lineages contained in two major clades; lineages 1 and 2 including class I UvrA and
class II UvrA2; lineage 3 including the Streptomyces class II UvrA. The class II UvrA2 proteins
form monophyletic clade with the class I UvrAs, supported by higher bootstrap value of 100 %.
This indicates that UvrA and UvrA2 from lineage 2 are closely related. However, the Streptomyces
class II UvrA proteins shares paraphyletic relationship with class I UvrA and class II UvrA2. This
suggests that the class II UvrAs have not diverged evolutionarily based on the deletion of the zincbinding motif and the UvrB-binding domain.
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Figure 3.14: Phylogenetic analysis of class I and II UvrA proteins. The evolutionary history was
inferred using the Neighbor-Joining method.91 The optimal tree is shown. The percentage of
replicate trees in which the associated taxa clustered together in the bootstrap test (100 replicates)
are shown next to the branches. The evolutionary distances were computed using the Poisson
correction method and are in the units of the number of amino acid substitutions per site.
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Figure 3.14: Sequence alignment of S. lasalocidi Ecm16 (slEcm16), S. nogalator SnorO
(snSnorO), S. peuceticus DrrC (spDrrC), X. axonopodis UvrA2 (xaUvrA2), D. radiodurans UvrA2
(drUvrA2), P. putida UvrA2 (ppUvrA2), B. stearothermophilus UvrA (bsUvrA), E. coli UvrA
(ecUvrA), M. tuberculosis UvrA (mtUvrA) and T. maritima (tmUvrA). Secondary structure of
Ecm16 is noted at the top. Absolutely conserved residues are highlighted in red, and highly
conserved residues are enclosed in blue. Conserved DNA-binding residues (black rectangle), Qloop (magenta star), zinc-coordinating residues (blue triangle), Walker A (green line), Walker B
(orange line) and α-helical ABC signature sequence (cyan line) are indicated at the bottom.
Sequence alignment was performed using ClustalW92 and the alignment figure was generated
using the ESpript 3.0 program.93
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3.4 CONCLUSION
The three-dimensional structure of Ecm16 protein was solved using X-ray crystallography
at 2.0 Å resolution. The structure of Ecm16 is resembles the class I UvrA protein form the
Nucleotide Excision Repair (NER) pathway in prokaryotes. The structure of Ecm16 lacks the
UvrB-binding domain and the zinc binding module 1. Therefore, the protein belongs to the class
II family of the UvrA homologues.
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Chapter 4: Biochemical characterization of Ecm16
4.1 BACKGROUND
The three-dimensional structure of Ecm16 is homologous to class I UvrA protein of the
Nucleotide Excision Repair (NER) pathway in prokaryotes. To better understand the mechanistic
insights of the antibiotic resistance, DNA binding activity of Ecm16 using undamaged and
echinomycin bound damaged DNA substrates was studied using Electrophoretic mobility shift
assay and fluorescence polarization assay was performed. This study will shed light towards
understanding the damage recognition mechanism of Ecm16. To understand the role of both
proximal and distal nucleotide binding site in Ecm16, ATPase assay was carried out, and the study
was supported by performing growth curve and mutagenesis experiments. The insertion domain
among various classes of UvrA is the most varied region. To elucidate the function of the Ecm16’s
insertion domain, biochemical characterization of Ecm16ΔID variant was performed.
4.2 MATERIALS AND METHODS
4.2.2 Fluorescence polarization assay
FAM labelled 32-mer DNA (Integrated DNA Technologies) containing echinomycin
binding site at the center was used to perform fluorescence polarization studies. The 32-mer
fluorescein-modified thymine in position 14 was used as an UvrA substrate.94 Binding studies was
protein to DNA was performed in the buffer containing 50 mM HEPES pH 7.5, 50 mM NaCl.
Reactions containing 50 nM dsDNA substrate were incubated at 25 °C for 30 min and
subsequently transferred to 384-well black coated microplate (Invitrogen) and read in a BioTek
Microplate Reader (Synergy HT, BioTek). The data for each protein concentration was processed
by subtracting the polarization values obtained from a respective DNA substrate without protein.
All assays were performed in triplicates and the Kd values were determined from a non-linear
dose-response curve in Prism pad. Error bars represent standard error of the mean.
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4.2.3 Purification of Ecm16 variants and UvrA
Nucleotide binding (Ecm16K56A and Ecm16K526A) and nucleotide hydrolysis
(Ecm16E399Q, Ecm16E708Q and Ecm16E399Q,E708Q) variants of Ecm16 were cloned between
the restriction enzyme digestion sites NdeI and EcoRI using the PCR based method of RestrictionFree (RF) cloning95 followed by DpnI enzyme digestion, transformation, and screening of positive
clones. The variants were purified using the procedure similar as wild-type Ecm16. The uvrApET28a (+) was a gift from Dr. Marcin Nowotny. UvrA protein was purified according to the
published protocol.94
4.2.4 ATPase assay
The ATP titration assay of the Ecm16 (0.2 µM) in ATPase reaction buffer (50 mM HEPES
pH 7.5, 50 mM NaCl, 10 mM MgCl2) at various ATP concentrations in presence of 1µM DNA or
DNA-echinomycin complex was measured with 2-amino-6-mercapto-7-methylpurine (MESG)
and purine nucleoside phosphorylase provided with the kit (Thermo Fisher Scientific). A microplate reader (Synergy HT, BioTek) was used to measure the UV absorbance at 360 nm. All assays
Ecm16 was incubated were carried out at 22°C, and the signal was read at every 30s. The data
points were fitted using non-linear regression analysis in Graphpad Prism.
An ATPase activity assay for Ecm16, K56A, K526A, E399Q, E708Q, E399 E708, Ecm16Δ ID,
Ecm16* and UvrA in presence of DNA or DNA-fluorescein or DNA-echinomycin or DNAdoxorubicin substrates was carried out under the same assay conditions, except for using one
concentration (1 mM) of ATP. A phosphate standard was measured to calibrate the UV absorbance
signal to the amount of inorganic phosphate release. To measure the initial ATPase rate, the data
points of linearly increasing interval were used for linear regression analysis.
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4.2.5 Growth curve assay using Ecm16 variants
The pBad-ecm16K56A, pBad-ecm16K526A, pBAD-ecm16E399Q, pBAD-E708Q, and
pBAD-ecm16E399QE708Q constructs were cloned, transform into K12 strain. Cultures were
grown in liquid media with ampicillin overnight from frozen stocks, incubated at 37°C and 200
rpm. Saturated culture was induced with a 0.2% arabinose solution for 30 minutes and used to
inoculate 2 ml duplicate replicate samples at a starting optical density of 0.02 OD600 in 13 mm
glass tubes. Cultures were grown in rich liquid media (LB), with Ampicillin and 0.2% Arabinose,
incubated at 37°C and 200 rpm. Optical density readings were taken every 30 minutes for 6 hours
using Thermo UV-Vis Spectrophotometer.
4.3 RESULTS
4.3.1 DNA binding activity of Ecm16
The electrostatic surface potential of Ecm16 reveals multiple positively charged residues
on the ventral surface of the protein (Figure 3.9). Therefore, DNA binding activity of Ecm16 in
the presence of normal DNA and DNA-echinomycin was studied by electrophoretic mobility shift
and fluorescence polarization assay. The DNA substrate contain the ACGT echinomycin binding
site at the center of the 32-mer oligonucleotide (Table 8.2). Ecm16 bound more efficiently to DNAechinomycin (Kd = 51.2 nM, Figure 4.1a, b) than to the drug-free DNA. Echinomycin recognizes
5′CpG3′ with a preference of flanked A·T pairs arranged in an alternating purine–pyrimidine
fashion.96. Echinomycin recognizes 5′CpG3′ with a preference of flanked A·T pairs arranged in
an alternating purine–pyrimidine fashion.96 To study whether Ecm16 shows any preference for its
DNA binding activity, DNA oligos with 100% GC and AT, 50-50 GC-AT composition were used
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to perform EMSA. Ecm16 bound with similar binding affinity for all the DNA substrates (Figure
4.1b), indicating that the protein would interact with the DNA backbone.

Figure 4.1: DNA binding activity of Ecm16. a, Binding of DNA or echinomycin-containing
DNA to Ecm16 visualized using electrophoretic mobility shift assay. Reaction mixtures
contained 32-bp DNA substrate in the absence (lane 1 and 2) or presence of 1, 2, 4, 8 and 16 nM
Ecm16 (lanes 3-12). b, Fraction of Ecm16 that has DNA-echinomycin bound plotted against
Ecm16’s concentration. Each data point represents the mean of three separate experiments. Kd
and Hill coefficient were determined using non-linear regression analysis using GraphPad
PRISM. c, Binding of Ecm16 to GC, AT and GC-AT rich 32 bp DNA substrates.
The DNA binding activity of Ecm16 was assessed using fluorescence polarization assay.
Consistent with the EMSA studies, FP assay shows that Ecm16 has lower binding affinity for FAM
attached DNA (Kd = 58.23 nM) compared to the echinomycin bound FAM attached DNA substrate
(Kd = 12.73 nM) (Figure 4.2). Since, most of the DNA interacting residues observed in the
damaged DNA-UvrA complex structure is conserved in the Ecm16, we hypothesize that the DNA
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damage recognition mechanism adopted by UvrA and Ecm16 might be similar. The binding
affinity of Ecm16 (Kd = 58.23 nM) and UvrA (Kd = 48.32 nM) were similar in presence of
undamaged DNA. In accordance with the previous results, UvrA showed slightly higher DNA
binding activity (48.32 and 27.37 nM) in presence of 32-mer DNA containing a fluoresceinmodified thymine (FT-DNA) compared to the normal DNA (FAM-DNA) (Figure 4.2). FT-DNA
is a known substrate for UvrA damage recognition. The binding affinity of UvrA for Ech-DNA
substrate was higher compared to the undamaged DNA and FT DNA (14.56 nM), suggesting that

Figure 4.2: Fluorescence Polarization assay of DNA binding activity of Ecm16 and UvrA. FP, in
millipolarization (mP) units is plotted as a function of protein concentrations. The error bars represent the
FP values as mean ± s.d. of triplicate experiments using the same buffer and protein conditions. The binding
affinity (Kd) values are shown in the table.
UvrA can recognize the echinomycin bound DNA substrate. UvrA detects DNA damage using an
indirect readout mechanism by sensing the DNA deformations.94 Therefore, the global unwinding
DNA perturbations caused due to echinomycin binding can be recognized by UvrA.
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4.3.2 Role of ATP binding and hydrolysis
To understand the role of ATP binding and hydrolysis in Ecm16 function, ATPase assays
were performed in the presence of DNA and DNA-echinomycin substrates. Ecm16 displayed
hardly any basal level ATPase activity in absence of substrates. The steady-state ATPase activity
was observed upon addition of DNA (Figure 4.3). This DNA substrate-dependent change in
ATPase activity indicates that the rate-limiting kinetic process occurs after Ecm16 binds to the
DNA. Surprisingly, the ATPase activity of Ecm16 increased ~17 times in presence of DNAechinomycin compared to DNA. These results differ from the ATPase activity of class I UvrA
where the steady-state ATPase rate remains relatively unchanged in presence of both undamaged
and damaged DNA.97

Figure 4.3: ATPase activity of Ecm16 (0.2 µM) measured at various ATP concentrations (0.0625,
0.375, 0.75, 1, 1.5 and 2 mM) in presence of 1 µM 32 bp DNA (red) and DNA-echinomycin (black)
substrates. The rate of hydrolysis is shown in µM/min. Each point corresponds to the average of
three separate measurements. Non-linear regression analysis (Michaelis-Menten) was applied to
the data points, using GraphPad PRISM, for obtaining the best-fit curve. The estimated kinetic
parameters (Vmax and Km) calculated for 32 bp DNA and DNA-Echinomycin are shown in red
and black respectively.
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To confirm that the drastic differences in ATPase activity between Ecm16 and Class I
UvrAs were not due to differences in purification or assay conditions, we purified UvrA from
Thermotoga maritima and determined its ATPase activity side by side with Ecm16 (Figure 4.5).
Consistent with previous observations 98,99, UvrA did not display significant differences in ATPase
activity between different types of substrates (Figure 4.4). Furthermore, the optimal ATPase
activity of Ecm16 was seven times higher compared to the optimal UvrA’s ATPase activity in the
presence of DNA-echinomycin (Figure 4.4).

Figure 4.4: Specific activity of Ecm16, Ecm16* and UvrA in the presence of 1 µM DNA, DNAechinomycin, DNA-fluorescein, and DNA-doxorubicin. Error bars represent standard deviation of
three independent experiments.
To study the role of critical residues in Ecm16’s nucleotide binding region, both the
proximal and distal ATP binding (K56A, K526A) and hydrolysis (E399Q, E708Q and E399Q,
E708Q) variants were analyzed for their ATPase activity. The lysine residue located in the Walker
A motif is known to interact with the β and γ phosphate in various NTPases100. The conserved
glutamate residue located within the Walker B motif can serve to polarize an incoming water
molecule which attacks the γ-phosphate during ATP hydrolysis101. We reasoned that replacement
of this residue with glutamine in Ecm16 can lead to severe inhibition of ATP hydrolysis and the
49

protein can be locked to active ATP bound confirmation. All variants of Ecm16 were purified with
>99 % purity (Figure 4.5a). The basal level of ATP hydrolysis of Ecm16 was no longer stimulated
in presence of DNA and the variants also showed complete loss of ATPase activity in presence of
DNA-echinomycin substrate (Figure 4.5b, Table 4.1). In vivo, none of the Ecm16 variants with
defects in ATP binding or hydrolyses were able to render echinomycin resistance to E. coli cells
(Figure 4.6, Table 4.1) Thus, our data reveal that Ecm16, a class II UvrA protein, requires both its
proximal and distal ATPase activities for its echinomycin resistance activity.

Figure 4.5: a, SDS-PAGE analysis of Ecm16, K56A, K526A, E399Q, E798Q, E399Q E708Q,
Ecm16ΔID, Ecm16*, and UvrA. Theoretical monomer mass Ecm16 and its variants, Ecm16ΔID,
Ecm16*, and UvrA is 86.3 kDa, 72.6 kDa, 86.1, 103.87 kDa, respectively. b, ATP hydrolysis assay
for Ecm16, K56A, K526A, E399Q, E708Q, E399Q, E708Q, Ecm16ΔID and Ecm16*.
Concentration of Ecm16 and DNA-echinomycin is 0.5 µM and 2.5 µM, respectively. Each data
point represents the mean of three separate experiments. The best-fit curve was obtained by
subjecting the data to linear regression analysis using GraphPad PRISM.
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Figure 4.6: Exponential state growth curves of Ecm16 variants K56A, K526A, E399Q, E708Q,
E399Q-E708Q, Ecm16ΔID and Ecm16*. Cultures were grown in rich media (LB) supplemented
with echinomycin (0 - 10 µM) and arabinose inducer (0.2 %). Error bars represent standard error
of the mean of duplicate replicate.
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Table 4.1: Doubling times based on exponential state growth curves of Ecm16, Walker A variants
(K56A and K526A), Walker B variants (E399Q, E708Q and E399Q, E708Q), Ecm16ΔID and
Ecm16* on a semi-logarithmic plot. Specific activity of Ecm16 variants in the presence of 1 µM
DNA-echinomycin. Error bars represent standard deviation of three independent experiments.

Protein
Ecm16
K56A
K526A
E399Q
E708Q
E399Q, E708Q
Ecm16ΔID
Ecm16*

E. coli doubling time (hours)
0 µM Ech
0.56 ± 0.08
0.64 ± 0.06
0.63 ± 0.06
0.50 ± 0.03
0.49 ± 0.02
0.48 ± 0.02
0.50 ± 0.03
0.50 ± 0.01

10 µM Ech
0.60 ± 0.10
no growth
no growth
no growth
no growth
no growth
no growth
no growth

ATPase specific activity
(nmol min-1 µg-1)
694.7 ± 37.6
8.0 ± 0.9
8.4 ± 1.0
9.5 ± 0.7
10.1 ± 0.5
9.3 ± 1.2
2.9 ± 0.4
42.9 ± 2.5

4.3.3 Essential role of the insertion domain of Ecm16
The insertion domain, proposed to be involved in DNA binding, shows substantial
conformational variability among class I and class II UvrA proteins.102 The insertion domains in
the class I bstUvrA structure are ~ 40 Å apart
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but those in the class II drUvrA2 structure are

~19 Å apart.104 Furthermore, other class I and II UvrA studies have shown that the ΔID variants
bind more efficiently to DNA compared to the wild-type proteins.65,103
Our structure of Ecm16 displays no atomic structure of the insertion domain suggesting that this
domain is mobile. To determine the role that the insertion domain plays in Ecm16, we constructed
a variant missing the insertion domain (Ecm16ΔID), purified (Figure 4.5a) and characterized its
DNA binding activity. (Figure 4.7). Unlike class I UvrA, Ecm16ΔID showed a complete loss of
DNA binding activity, both in presence and absence of echinomycin.

52

Figure 4.7: a. Reaction mixtures contained DNA or DNA-echinomycin or DNA-doxorubicin
substrate in the absence (lane 1) or presence of 100, 200, and 300 nM Ecm16 (lanes 2-4),
Ecm16ΔID (5-7) and Ecm16* (8-10) b, Fluorescence Polarization assay of DNA binding activity
of Ecm16 and UvrA. FP, in millipolarization (mP) units is plotted as a function of protein
concentrations. The error bars represent the FP values as mean ± s.d. of triplicate experiments
using the same buffer and protein conditions.
To differentiate between the insertion domain playing a role in DNA binding versus a role
in providing substrate specificity, we constructed a variant, referred to as Ecm16*, where the native
insertion domain was swapped with that of a different class II UvrA protein, DrrC, from S.
peucetius (Figure 4.5a). DrrC was previously proposed to confer resistance to the DNA intercalator
drug daunorubicin.105-107 Ecm16* bound DNA-echinomycin and DNA-doxorubicin with similar
high affinity, but it bound weakly to normal DNA (Figure 4.7a). This result indicates that insertion
domain is a necessary structural element for DNA binding and that it enables Ecm16 to distinguish
damaged DNA from normal DNA. In the scenario where the insertion domain is exclusively
involved in DNA binding, Ecm16*, unlike Ecm16ΔID, should be able to rescue E. coli cells
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exposed to echinomycin. However, our in vivo analyses revealed that neither the Ecm16Δ ID nor
the Ecm16* variant could render resistance against echinomycin in E. coli (Figure 4.6, Table 4.1).
This difference in activity was explained by analyzing the ATPase activity of Ecm16*. Although
Ecm16* can bind DNA-echinomycin with similar affinity as Ecm16, the modified amino acid
sequence of the insertion domain in Ecm16* renders the protein unable to hydrolyze ATP. The
Ecm16ΔID displayed almost no detectible ATPase activity (~3 nmol min-1 µg-1) (Figure 4.4).
Ecm16* that contains an insertion domain from a different UvrA2 increased its ATPase activity
(~43 nmol min-1µg-1) but this rate is nowhere close to the activity of wild-type Ecm16 (~700 nmol
min-1µg-1). These data revealed that the insertion domain of Ecm16 plays two independent roles:
binding of DNA substrate and regulation of substrate-dependent ATP hydrolysis activity.
4.4 CONCLUSION
Ecm16 is an DNA binding protein and shows nucleotide independent mode of DNA
binding. The protein has higher binding affinity for echinomycin-DNA substrate compared to the
undamaged DNA. ATPase activity of Ecm16 is accelerated by the DNA binding event and the rate
of ATP hydrolysis is higher in presence of echinomycin-DNA substrate. Based on the biochemical
characterization of Ecm16, the molecular mechanism of recognition of damaged DNA is like the
UvrA protein. Unlike class I UvrA, the role of the insertion of Ecm16 is different. The insertion
domain of Ecm16 is directly involved in DNA binding.
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Chapter 5: Molecular mechanism of echinomycin antibiotic resistance
5.1 BACKGROUND
Based on the structural and biochemical data, we propose the DNA damage recognition
mechanism of Ecm16 to be similar as the class I UvrA. It is interesting to understand how Ecm16
lacking UvrB-binding domain undergoes damage verification and repair steps. To validate
whether, the UvrB, UvrC and UvrD proteins play any role towards damage repair caused by
echinomycin, growth curve studies was performed using K12∆uvrA, K12∆uvrB, and K12∆uvrC
strains and ecm16 was expressed. Based on the biochemical experiments, if Ecm16 can recognize
the substrates of NER pathway, it would be interesting to study whether the protein can
complement UvrA’s function of UvrB recruitment. To answer this, colony forming unit assay was
performed using K12∆uvrA and expressing Ecm16.
5.2 MATERIALS AND METHODS
5.2.1 Growth curve assay
The Keio collection E. coli strains of K12∆uvrA, K12∆uvrB, and K12∆uvrC were ordered
from Coli Genetic Stock Center (CGSC). The pBad-ecm16 plasmid was used to transform K12
(Keio Collection parent strain), K12∆uvrA, K12∆uvrB, and K12∆uvrC E. coli strains using
electroporation. Each K12 strain was also transformed with a pBad vector control with no insert.
Ampicillin was used to select positive transformations and confirmed using colony PCR. Cultures
were grown in liquid media with ampicillin overnight from frozen stocks, incubated at 37°C and
200 rpm. Saturated culture was induced with a 0.2% arabinose solution for 30 minutes and used
to inoculate 2 mL duplicate replicate samples at a starting optical density of 0.02 OD600 in 13 mm
glass tubes. Cultures were grown in rich liquid media (LB), with Ampicillin and 0.2% Arabinose,
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incubated at 37°C and 200 rpm. Optical density readings were taken every 30 minutes for 6 hours
using Thermo UV-Vis Spectrophotometer
Brevibacillus competent cells were ordered from Takara Bio. The pNI plasmid was
transformed into according to the manufacturer’s instructions. 2-4 colonies were inoculated at
37°C and 200 rpm in the 2SYF liquid medium supplemented with 50 µg/ml neomycin antibiotic.
The overnight grown culture was diluted using 2SYF liquid medium upto OD600 0.02-0.05.
Purified Ecm16 or buffer (50 mM HEPES pH 7.5, 50 mM NaCl) was added to echinomycin at
molar ratio of 1:1 and 10:1 and incubated at room temperature for 30 minutes. Two concentrations
50 and 100 nM of echinomycin were used. This mixture was added to the Brevibacillus cells in
the 2SYFNm medium, and the optical density was monitored every 30 minutes for 20 hours using
96-well multiplate reader (Synergy HT, Biotek).
5.2.2 Colony Forming Units
Cultures were grown overnight incubated at 37°C and 200 rpm in liquid media with
ampicillin and used to inoculate samples to 0.3 OD600 the following day. 0.2% arabinose was added
to each sample and cells were incubated for 2 h. Cells were then serially diluted by factors of 10
and 5 µL of cultures were spotted on LB/Ampicillin plates with 0.2% Arabinose. Plates were
exposed to ultraviolet radiation (nm) at 5 J/m2 or 10 J/m2 or no UV as a negative control.
5.2.3 SPR-based assay
Purified Ecm16 was immobilized using amine-coupling chemistry on the surface of
carboxyl sensor chip (Nicoya Lifesciences). The carboxyl groups on the matrix of the chip were
activated using 0.04 mM N-hydroxysuccinimide/0.3 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (NHS/EDC) to form N-hydroxysuccinimide esters. The Ecm16 ligand (1 µM) was
diluted in SPR running buffer (50 mM HEPES pH 7.5, 50 mM NaCl) and flowed over the activated
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chip surface for 5 min at a rate of 20 μL/min, to ensure the spontaneous reaction of the ester with
the primary amines on the protein to form covalent links. The remaining activated carboxyl groups
were blocked using blocking buffer containing 1 M ethanolamine at pH 8.0. Echinomycin was
diluted at 0.5, 2, 4 and 6 µM concentrations and flowed over the immobilized Ecm16 for 5 minutes
at the rate of 20 µL/min. Dissociation was measured for over 3 minutes. All these assays were
performed at 22 °C. The kinetic parameters, dissociation rate constants (kon and koff) and the
equilibrium dissociation constant (Kd) were obtained from globally fitting (nonlinear regression)
the Langmuir model, implemented in TraceDrawer analysis software, to entire sensograms
(association and dissociation phases) obtained by injecting different analyte concentrations.
5.3 RESULTS
5.3.1 Ecm16’s echinomycin resistance activity does not require components of the NER
system.
Based on the structural similarities between Ecm16 and UvrA, we examined whether
Ecm16’s mechanism of protective action against echinomycin resembles the activity of the DNA
repair protein UvrA. In E. coli, UvrA detects DNA damage and begins the cascade of recruitment
of UvrB/C/D proteins of the NER system.108 Even though the most significant contact between
UvrA and UvrB is through UvrB-binding domain, the UvrAB complex structure shows the
interaction of signature II domain of UvrA with the E295 and E299 residues of UvrB (Figure
5.1).109 To address the possibility that Ecm16’s echinomycin resistance activity might require
ransient interaction with the NER components, we analyzed E. coli strains with knockouts of each
individual component (uvrA, uvrB, uvrC, and uvrD; Keio Collection) 110 (Figure 5.2). To each of
these strains, we transformed the replicating plasmid encoding ecm16 or VCO. We tested the
ability of these strains to grow in the presence of echinomycin concentrations that were tolerated
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by cells expressing ecm16. Our growth analyses revealed that cells encoding the NER system and
cells without components of the NER system presence of echinomycin. Ecm16 was able to provide
the same level of echinomycin resistance in the absence of NER.system displayed similar doubling
rates.

Figure 5.1: The molecular envelope of the AB sensor complex calculated from solution SAXS
data is depicted as a gray mesh. (b) Isothermal titration calorimetry analysis reveals that the A:B
stoichiometry of the complex is 2:2. (c, d) The UvrA-UvrB interface seen in the crystal structure
(c) and its verification by mutation (d). (Adapted from Pakotiprapha, et al., 2012).
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Figure 5.2: Exponential state growth curves (n = 3) of E. coli K12 strains with different
components of the native nucleotide excision repair system (NER) knocked out (ΔuvrA, ΔuvrB,
ΔuvrC or ΔuvrD) and carrying vector-control-only or vector encoding ecm16. Cultures (2 mL)
were set to OD600nm ~ 0.2 in rich media (LB) supplemented with the inducer (0.2% arabinose)
and varying concentrations of echinomycin (0 - 10 µM). Growth was monitored by measuring the
absorbance at 600 nm every 30 minutes. E. coli K12 NER knockouts show similar patterns of
resistance to echinomycin in the presence of inducer for the expression of ecm16. Results are
shown for exponential growth phase with exponential trend line, error bars represent SEM of
duplicate replicates. All results shown are representative of three independent replicates.
5.3.2 Ecm16 and UvrA cannot complement each other’s function.
In E. coli, the activity of UvrA is essential for repairing various types of DNA damage
including thymine dimers caused by UV radiation.111 To determine whether Ecm16 can
complement UvrA’s activity, we examined the ability of various strains to recover from UV
radiation using Colony Forming Unit (CFU) assays (Figure 5.3). E. coli cells with their native
uvrA gene and VCO can effectively recover from 5 J/m2 of UV radiation exposure as evidenced
by the similar number of CFUs compared to the no-radiation control. However, the cell’s ability
to recover from UV radiation is significantly reduced when E. coli’s native uvrA gene is knocked
out. Once uvrA was expressed in trans from a replicating plasmid under the control of the arabinose
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inducible promoter, the ability to repair DNA damage was fully recovered. These data are in
accordance with previous analyses of uvrA knockout strains112.

Figure 5.3: Colony Forming Unit (CFU) assays after UV radiation. 5 µL of cultures grown to
OD600nm ~0.2 were serial diluted (dilution factor = 5 x 10-1 to 10-6) and spotted on LB plates
supplemented with 0.2% arabinose. Cultures included the following strains: control sample (top
row) are wild-type cells with vector-control-only, test samples (middle 2nd and 3rd rows) are strains
with the native E. coli’s uvrA gene knocked out and with vector-control-only or vector encoding
ecm16, complementation control strain (bottom row) encodes E. coli’s native uvrA gene in the
same pBAD vector. Freshly spotted plates were exposed to UV radiation and then incubated at 37
C for 18 h prior to imaging. The data shown are a representative of three independent replicates.
However, when the gene encoding for Ecm16 was expressed in trans from the same
replicating plasmid controlled by the arabinose promoter, E. coli cells were unable to recover from
UV radiation. The number of CFUs of the strain expressing ecm16 was as diminished as the CFUs
observed on the uvrA knock out strain. The same trend of UV resistance was observed among the
E. coli strains when higher level of radiation (10 J/m2) was used. The inability of Ecm16 to
complement a uvrA knockout strain suggest that Ecm16 is unable to recognize thymine dimers
and/or recruit the rest of the NER system for classical DNA repair. However, even though UvrA
can recognize the DNA distortion caused due to echinomycin binding (Figure 4.2), it fails to
provide resistance against echinomycin. Damaged DNA that are substrates of the NER system
have a ~30º kink, but they retain the length and helicity of B-form DNA. We propose that the
failure of NER system to confer resistance against echinomycin might be due to the inhibition of
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the helicase activity of UvrB. After damage recognition by UvrA, UvrB is recruited which forms
pre-incision complex. Out of the five domains 1a, 1b, 2, 3 and 4 present in UvrB, domain 1a and
3, belong to the helicase II family and shares high structural similarity to the DNA helicases like
PcrA and Rep. The strand separation activity of the helicase II is inhibited in presence of bulky
DNA intercalators like nogalamycin and mitoxantrone113. UvrB requires certain level of bent
duplex DNA to initiate its translocation activity. However, echinomycin bound DNA helix is
straight, lengthened by ~10 Å and is completely unwound.114 Such distorted DNA substrate is not
ideal for loading of UvrB’s strand separation activity. Another possible explanation is the repair
of echinomycin-bound DNA should not require a helicase protein since it is already unwound at
the damage detection stage. This is in line with the observation that UvrA contains a UvrB binding
domain, but that Ecm16 does not.
5.3.3 Binding activity of Ecm16 for echinomycin
SPR studies was performed to determine the interaction of Ecm16 with echinomycin. The
carboxyl groups on the matrix of chip were activated using EDC/NHS at the flow rate of 20 µl/min.
As shown in figure 5.4a, the baseline changed after the addition of EDC/NHS, which resulted in
the formation of N-hydroxysuccinimide esters. These functionalized was treated with purified
Ecm16 at the flow rate of 20 ul/min for 5 minutes. Further, the chip surface was treated with 1 M
ethanolamine (pH 8.0) to quench excess aldehyde groups. The SPR result of the immobilization
of purified Ecm16 onto the carboxyl surface is shown is figure 5.4a.
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Figure 5.4: a, SPR response of purified Ecm16 binding on the functionalized carboxyl chip. b, SPR
measurement of Ecm16 binding to echinomycin measured in buffer containing 50 mM HEPES pH 7.5, 50
mM NaCl.
Various concentrations of echinomycin diluted in the running buffer were flowed over the
Ecm16 immobilized sensor chip for the association time of total 300s. After the quasi-equilibrium
is reached, running buffer was flowed over the chip surface to break the interaction between the
Ecm16 and echinomycin for the 180s at 20 µl/min flow rate. Figure 5.4b shows the SPR response
versus the echinomycin concentrations. The experimental data was fitted using the following
equation 4,
𝑅=

𝑅𝑚𝑎𝑥 [𝐴]
𝐾𝑑+[𝐴]

………………………………………………………….. 5

where R is the SPR equilibrium response, Rmax is fitting parameter representing maximum
response, and [A] is the analyte (echinomycin) concentration. We obtained Kd value of ~9.1 µM
for the Ecm16 and echinomycin concentrations. The running buffer used in the SPR studies does
not contain any nucleotide and the purified Ecm16 is ADP bound. This result indicates that the
protein can bind echinomycin in the ADP bound conformation. In line with this results, the
background ATPase activity of Ecm16 remained unchanged after addition of echinomycin in the
solution.
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5.3.4 Effect of Ecm16-echinomycin binding on bacterial growth
Binding of echinomycin to Ecm16 can contribute towards rescuing of bacterial cells from
the cytotoxic effects of echinomycin. To test this hypothesis, growth curve studies was

Figure 5.5: Growth curve studies of Brevibacillus cells in presence of buffer or echinomycin or
Ecm16 or Ecm16-echinomycin. Echinomycin is denoted as Ech. Cultures were grown in 2SYNm
medium supplemented with or without echinomycin (50 and 100 nM) or Ecm16 or Ecm16echinomycin. Error bars represent standard error of the mean of duplicate replicates.
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performed using Brevibacillus cells, where the pre-formed Ecm16-echinomycin complex was
added to the cells and growth rate was monitored. The echinomycin sensitive Brevibacillus cells
were transformed with a low copy pNI vector. in absence of echinomycin antibiotic, Brevibacillus
cells reached saturation (OD600 ~1.8) within a 20-hour growth period (Figure 5.5) without
echinomycin. The cells, when treated with 50 and 100 nM echinomycin concentration, reached
~1.4 and ~0.2 OD600nm within the same 20-hour period respectively. Brevibacillus cells incubated
with purified Ecm16 at 50, 100, 500 and 1000 nM concentrations reached equivalent maximal
densities when grown in the absence of echinomycin (Figure 5.5). The protein was incubated with
echinomycin at 1:1 and 10:1 molar ratio at room temperature for 30 minutes, added to the 2SYNm
medium containing the Brevibacillus cells. In presence of Ecm16 added ten times higher than
echinomycin, cells were able to maintain doubling rate better than the control cells containing
echinomycin. These results were consistent for both 50 and 100 nM echinomycin concentration.
Table 5.1: Doubling times based on exponential state growth curves of Echinomycin, Ecm16 and
Ecm16-echinomycin.
Echinomycin (nM)
Buffer
Echinomycin
Ecm16 (1:1)
Ecm16 (1:10)
Echinomycin: Ecm16 (1:1)
Echinomycin: Ecm16 (1:10)

50
0.94 ± 0.06
1.67 ± 0.04
1.02 ±0.07
0.95 ± 0.04
1.35 ± 0.05
1.01 ± 0.05

100
0.96 ± 0.03
66.01 ± 0.06
0.95 ± 0.06
0.99 ± 0.02
47.80 ± 0.04
4.74 ± 0.03

5.4 CONCLUSION
The molecular mechanism of antibiotic resistance against echinomycin by Ecm16 is
independent of the UvrA, UvrB, UvrC and UvrC components of the NER pathway. Despite of
high structural similarity between class I UvrA and Ecm16, the proteins fail to complement each
other’s function in vivo. Ecm16 binds echinomycin independent of DNA, suggesting the antibiotic
dislodging mechanism of antimicrobial resistance.
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Chapter 6: Substrate specificity of Ecm16 towards DNA bisintercalating compounds
6.1 BACKGROUND
The Nucleotide Excision Repair pathway in prokaryotes provides a broad specificity
towards its substrates. To study whether, Ecm16 can also recognize and provide resistance against
various antibiotics which are DNA interacting compounds, disk-diffusion and growth curve
studies was performed using Brevibacillus system.
6.2 MATERIALS AND METHODS
6.2.1 Plasmid construction and expression
ecm16 gene containing BamHI and XbaI restriction digestion enzymes at the 5’ and 3’
respectively was PCR amplified, ligated with pNI-His DNA vector (Takara, Cat # HB132) and
transformed in TOP10 E. coli competent cells. The pNI-His-ecm16 construct was transformed
using New-Tris PEG (NTP) method into the Brevibacillus expression strain according to the
manufactures protocol. Briefly, 100 ng of plasmid DNA was mixed with solution A and the
mixture was used to resuspend the bacterial cell pellet. Further, PEG containing solution B was
added to the bacterial cells, centrifuged and the final cell pellet was resuspended using 1 ml of MT
medium. The composition of MT liquid medium is glucose (10.0 g/L), phytone peptone (10.0 g/L),
35% ehrlich bonito extract (5.75 g/L), yeast extract blue label (2.0 g/L), FeSO4・7H2O (10 mg/L),
MnSO4・4H2O (10 gm/L), ZnSO4・7H2O (1 mg/L), MgCl2 (4.1 g/L). The cells were incubated
at 37°C for 3 hours in an orbital shaker, plated into MT medium containing 50 µg/ml neomycin
and cultured overnight at 37°C.
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6.2.2 Expression of Ecm16 using recombinant Brevibacillus system
2SYF medium was used to perform the expression analysis of pNI-His-ecm16. 2SYF
medium consists of fructose (20.0 g/L), bacto Soytone (40.0 g/L), bacto yeast extract (5.0 g/L) and
CaCl2・2H2O (0.15 g/L). Neomycin antibiotic was added to the medium at the concentration of
50µg/ml. 4-6 colonies of pNI-His-ecm16 transformed cells were inoculated in 3 ml of 2SYFNm
media and incubate at 30℃ with shaking at 120 rpm for 48 - 64 hours. Sampling was performed
every 24 hours to check the production of Ecm16 protein. At the end of incubation, cells were
isolated using centrifugation at 5,000 g for 15 minutes and resuspended in 1X PBS buffer.
6.2.3 Agar Disk-diffusion Assay
All the antibiotics used in the study were purchased (Cayman Chemicals) in the powdered
form and dissolved in their respective solvents. The sterile 10 mm disks (Sigma Aldrich) were
loaded with varying quantities of echinomycin, doxorubicin, daunorubicin, actinomycin D,
mithramycin A, thiocoraline, quinaldopeptin, sandramycin and dried. pNI or pNI-ecm16
transformed Brevibacillus cells were mixed well with the molten MT agar medium and poured
onto petri dishes. The antibiotic loaded disks were placed onto the plates and incubated at 37 °C
overnight.
6.3.3 Growth curve assay
Cultures were grown in liquid MT media with neomycin overnight from frozen stocks,
incubated at 37°C and 200 rpm. Saturated culture was diluted upto optical density of 0.02- 0.05
OD600 and further grown in the MT media. Optical density readings were taken every 30 minutes
for 20 h using 96-well multi-plate reader (Synergy HT, BioTek).
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6.3 RESULTS
6.3.1 Ecm16 provides partial resistance against quinaldopeptin, thiocoraline and
sandramycin DNA bisintercalators.
ecm16 gene was cloned into pNI-His vector and transformed into Brevibacillus, yielding
recombinant strain expressing Ecm16 protein (Figure 6.1). The antimicrobial resistance activity of
Ecm16 was tested against various DNA interacting drugs which have intercalation, cross-linking,
free-radical formation, and minor grove binding mechanism of action. The actinomycin D, isolated
from various Streptomyces strains, contain phenoxazine chromophore attached to two cyclic
depsipeptides (Figure 6.2). This molecule acts as an DNA intercalator as wells a minor grove
binder.115 116 Daunorubicin and doxorubicin belongs to the anthracycline family of antibiotics and
damage DNA by intercalation and free radical formation which causes DNA alkylation and crosslinking (Figure 6.2).
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Both doxorubicin and daunorubicin are used clinically for the treatment

for different forms of cancers.118 Mithramycin belonging to the aureolic acid family of antibiotics

Figure 6.1: SDS-PAGE analysis of expression of ecm16 in Brevibacillus system.
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can bind bivalent cations and form high-affinity metal-antibiotic complex, which can interact with
DNA via minor groove.119 Quinaldopeptin, sandramycin, thiocoraline and echinomycin are DNA
bisintercalating compounds, where the two chromophore rings are inserted between the base-pairs
of DNA duplex and the cyclic depsipeptide is placed into DNA minor groove.120 All the
compounds and their mechanism of action used in the study is summarized in Table 6.1.
Compounds were tested for their susceptibility against Brevibacillus bacteria at various
concentrations using disk-diffusion assay.
Disk diffusion assay revealed that actinomycin D, mithramycin A, doxorubicin,
daunorubicin, quinaldopeptin and echinomycin showed more susceptibility compared to
sandramycin and thiocoraline antibiotic in Brevibacillus. Ecm16 showed complete resistance
against echinomycin (10 µg).
Table 6.1: List of DNA binding antibiotics and their mechanism of action on DNA
Compound
Mechanism of Action
Actinomycin D
Monointercalation and minor groove binder
Daunorubicin
Covalent intercalation and cross linker
Doxorubicin
Covalent intercalation and cross linker
Luzopeptin A
Bisintercalation and minor groove binder
Mithramycin A
Minor groove binder
Quinaldopeptin
Bisintercalation and minor groove binder
Sandramycin
Bisintercalation and minor groove binder
Thiocoraline
Bisintercalation and minor groove binder
Unlike daunorubicin, which is sensitive to gram positive brevibacillus at 100 and 10 µg
amounts, doxorubicin was susceptible only for 100 µg amount (Figure 6.2). Zone of inhibition was
observed for 100, 50 and 10 µg amounts for both actinomycin D and mithramycin A antibiotics.
Among DNA bisintercalators, quinaldopeptin showed the highest sensitivity and the thiocoraline
was least sensitive. Disk diffusion assay revealed that Ecm16 failed completely to provide
resistance against doxorubicin, daunorubicin, actinomycin D, mithramycin A (Figure 6.2).
However, the Brevibacillus cells expressing Ecm16 were resistant against quinaldopetin,
sandramycin, thiocoraline, antibiotics upto certain extent. The Brevibacillus bacteria was not
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recovered fully, indicating the partial resistance effect against DNA bisintercalators except for
echinomycin antibiotic (Figure 6.2).
To confirm the partial resistance activity of Ecm16 against quinaldopeptin, sandramycin,
and thiocoraline antibiotics, growth curve experiments were performed. In absence of antibiotics,
Brevibacillus cells with reached saturation (OD600nm ~1.8-2.0) within a 16 h growth period (Figure
6.3). The cells grown in the presence of 25 and 50 nM echinomycin only reached ~1.5 OD600nm
within the same 6 h period. Almost no detectable growth was observed for VCO cells at
echinomycin concentration of 100 nM and higher.
However, Brevibacillus cells expressing ecm16 reached equivalent maximal densities
when grown in the presence or in the absence of supplemented echinomycin (Figure 6.3a). The
cells grown in presence of 1.5 and 3 µM quinaldopeptin antibiotic shown no obvious change in
the growth rate, but no cell growth was observed at 6 µM concentration (Figure 6.3b). Expression
of Ecm16 provided partial resistance at 6 µM concentration. At lower concentrations of
quinaldopeptin, cells expressing ecm16 didn’t not reach maximal densities. Similar trend was
observed for cells growing in presence of thiocoraline and sandramycin antibiotics (Figure 6.3c,
d). Using growth curve analyses, we determined the effect of ecm16 expression on doubling rates.
In the absence of echinomycin, Brevibacillus cells with or without expression of ecm16 were able
to double every ~0.7-0.9 h under our experimental conditions. However, in the presence of
echinomycin, the doubling rate increased more than 10-fold at the highest 100 nM concentration.
In presence of 6 µM concentration of quinaldopeptin, cells expressing ecm16 had the doubling rate
6-fold higher. For cells grown in presence of thiocoraline and sandramycin, the growth rate
improved by 3-fold and 4-fold in the cells expressing ecm16. Altogether, these results indicates
that Ecm16 provides partial resistance against DNA bisintercalators and fails to recover cells
grown at lower concentrations of DNA bisintercalating drugs.
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Figure 6.2: Disk-diffusion assay to study the antibiotic resistance activity of Ecm16 against
doxorubicin, actinomycin D, daunorubicin, mithramycin A, sandramycin, thiocoraline,
quinaldopeptin antibiotics in Brevibacillus cells. Echinomycin (10 µg) was used as control in each
plate. pNI and pNI-ecm16 plasmids were transformed into Brevibacillus.
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Figure 6.3: Growth curves of pNI and pNI-ecm16 transformed Brevibacillus cells. Cultures
were grown in 2SYNm medium supplemented with a, echinomycin b, quinaldopeptin c,
thiocoraline and d, sandramycin at various concentrations. Error bars represent standard error
of the mean of triplicates.
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Table 6.2: Doubling times based on exponential state growth curves of pNI and pNI-ecm16
transformed Brevibacillus cells grown in presence of echinomyin.
Echinomycin
(nM)
0
25
50
100

pNI (h)

pNI-ecm16 (h)

0.99 ± 0.02
1.61 ± 0.05
1.99 ± 0.05
10.38 ± 0.08

0.91 ± 0.06
0.94 ± 0.02
0.92 ± 0.02
0.97 ± 0.06

Table 6.3: Doubling times based on exponential state growth curves of pNI and pNI-ecm16
transformed Brevibacillus cells grown in presence of quinaldopeptin.
Quinaldopeptin
(µM)
0
1.5
3.0
6.0

pNI (h)

pNI-ecm16 (h)

0.87 ± 0.01
1.12 ± 0.09
1.51 ± 0.12
5.92 ± 0.14

0.86 ± 0.12
1.12 ± 0.16
1.18 ± 0.09
1.15 ± 0.10

Table 6.4: Doubling times based on exponential state growth curves of pNI and pNI-ecm16
transformed Brevibacillus cells grown in presence of thiocoraline.
Thiocoraline
(µM)
0
0.5
2.0
4.0

pNI (h)

pNI-ecm16 (h)

0.71 ± 0.08
1.14 ± 0.13
1.35 ± 0.12
3.12 ± 0.09

0.77 ± 0.06
1.13 ± 0.11
1.02 ± 0.07
1.02 ± 0.08

Table 6.5: Doubling times based on exponential state growth curves of pNI and pNI-ecm16
transformed Brevibacillus cells grown in presence of sandramycin.
Sandramycin
(µM)
0
0.5
1.0
2.0

pNI

pNI-ecm16

0.84 ± 0.06
1.08 ± 0.09
1.89 ± 0.11
5.41 ± 0.19

0.86 ± 0.04
1.08 ± 0.07
1.40 ± 0.15
1.42 ± 0.13

72

6.2 CONCLUSION
Brevibacillus cells expressing Ecm16 in presence of doxorubicinn, daunorubicin,
actinomycin D, mithramycin A fail to grow normally, indicating the protein could not provide
resistance. However, Ecm16 conferred partial resistance against quinaldopeptin, thiocoraline and
sandramycin DNA bisintercalators. Therefore, Ecm16 shows specificity for the DNA
bisintercalating category of antibiotics. This result differs from the class I UvrA system, where the
protein recognizes a wide array of DNA damages, which are further repaired by the other NER
components.
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Chapter 7: Discussion, conclusion, and future directions
Living organisms are continuously exposed to different types of DNA damage. The
nucleotide excision repair (NER) system is a conserved system that enables cells to thrive by
detecting and repairing a wide variety of DNA lesions. The NER systems of bacteria and
eukaryotes share broadly the same sequence of events: damage recognition, excision of damage,
and synthesis to fill in gap. In bacteria, the NER system consists of four proteins: UvrA, UvrB,
UvrC, and UvrD. Briefly, UvrA recruits the UvrB, a helicase, which separates the two strands and
recruits UvrC, an endonuclease, to the lesion site which cleaves the phosphodiester bond eight
nucleotides upstream and up to five nucleotides downstream of the modified nucleotide. Next,
UvrC recruits UvrD, another helicase, which displaces the cleaved DNA fragment. Finally, DNA
polymerase I synthesizes the missing stretch of DNA using the undamaged complementary strand
as a template and DNA ligase seals the breaks, thus completing the repair.
DNA lesions repaired by NER include pyrimidine dimers78,79, unpaired T and G residues80,
backbone modifications such as single nucleotide gaps and nicks81-84, and adducts of
anthramycin81,85,86, cholesterol87, fluorescein84, and polypeptides88. The unusually broad substrate
specificity of NER is attributable to UvrA or the UvrA-UvrB2 complex, the proposed damage
sensor component of NER. X-ray crystal structure of four UvrA including one structure complexed
with UvrB (UvrA-UvrB2) have been reported so far. In 2008, the crystal structure of ADP-bound
UvrA from Bacillus stearothermophilus revealed that UvrA is a homodimer, where each protomer
contains two nucleotide binding sites and three zinc coordination sites.104 In 2009, the crystal
structure of UvrA from Thermotoga maritima in complex with a 32-bp DNA containing a
fluorescein-modified thymine, mimicking UV-damaged DNA, showed that UvrA contacts DNA
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on either side of the modification, instead of directly at the damage site.89 This structure supports
the hypothesis that UvrA detects DNA lesions by recognizing the perturbation in DNA topology
rather than the chemical modification. In 2011, the crystal structure of UvrA from Mycobacterium
tuberculosis led to the hypothesis that ATP hydrolysis is associated with movement of the UvrB
binding domain.121 In 2012, the crystal structure of the UvrA-UvrB2 complex from Geobacillus
stearothermophilus showed that one UvrB binds to each end of the UvrA homodimer, thus forming
an elongated protein complex with a continuous DNA binding groove.122 The UvrA in this
structure has a narrow and deep DNA-binding groove, as opposed to the wide and shallow groove
seen in previous crystal structures, highlighting the dynamic nature of UvrA. Despite extensive
structural and biochemical studies on UvrA, the DNA damage recognition mechanism remains
unclear. One school of thought is that the UvrA homodimer carries out DNA lesion detection alone
89,123

, while a second school of thought is that the UvrA-UvrB2 complex performs lesion

detection.122,124,125
UvrA belongs to the superfamily of ATP-binding cassette (ABC) ATPases that include two
extra domains: UvrB-binding domain and insertion domain (ID). In addition to the canonical
UvrA, several bacterial phyla (including Actinobacteria, Firmicutes, Bacteroidetes and
Proteobacteria) also express a class II UvrA.126 The only reported class II UvrA crystal structure
to date is that of the truncated UvrA2 from Deinococcus radiodurans, which revealed that class I
and class II UvrA are structurally homologous.127 UvrA2 lacks the UvrB-binding domain and its
associated zinc-binding motif. Determining the specific function(s) of class II UvrA proteins has
remained elusive. In D. radiodurans, expression of uvrA and uvrA2 gene is upregulated following
ionizing radiation.128 However, deletion of the uvrA2 gene had no effect on the cell’s UV
sensitivity.129 In Xanthomonas axonopodis and Pseudomonas putida, the double knockout ΔuvrA
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ΔuvrA2 displayed slightly higher sensitivity to high UV radiation compared to the single knockout
ΔuvrA suggesting that UvrA2 can contribute, although at a minor level, to the repair of UV-induced
DNA damage.130 In P. putida, UvrA2 was proposed to also be involved in mutagenesis
mechanisms during stationary growth phase.131 Overall, our knowledge about the specific roles
that class II UvrA proteins play in bacteria remains obscure.
In this study, we provide a comprehensive characterization of the mechanism of a class II
UvrA protein. Our work provides new insights into how class II UvrA proteins catalyze various
functions that are independent of the evolutionarily related protein UvrA. Our data also suggest a
potential mechanism that allows Ecm16 to function in DNA repair independently from the NER
system. Our data demonstrated that expressing ecm16 is sufficient to confer echinomycin
resistance to an otherwise echinomycin sensitive bacterium, E. coli K12. We showed that the
DNA-binding and ATP hydrolysis of Ecm16 are required for its ability to render resistance. These
activities are in line with the crystal structure of Ecm16 which contains four nucleotide binding
sites and a prominent DNA-binding groove at the ventral side. Despite the structural similarity to
UvrA, Ecm16 could not complement the activity of UvrA in repairing DNA damage caused by
UV radiation. Furthermore, Ecm16 was able to confer echinomycin resistance to host cells which
are deficient in UvrB, UvrC, or UvrD, indicating that Ecm16 does not depend on the NER
machinery for its function.
We have shown that the insertion domain plays an essential role for Ecm16’s ability to
render echinomycin resistance. Removing the insertion domain of Ecm16 results in the loss of
affinity for DNA and significantly reduced affinity for DNA-echinomycin. In D. radiodurans, the
drUvrA2ΔID was shown to bind undamaged DNA with the similar affinity as the full length
drUvrA2, and only displayed a mild reduction in affinity with damaged DNA.65 One potential
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explanation to this minimal role of the ID observed in drUvrA2 is that UV-damaged DNA may
not be the true substrate of drUvrA2 given that drUvrA2 displays no effect on D. radiodurans’ UV
resistance.129 Notably, we have shown that the specific primary sequence of the insertion domain
in Ecm16 does not determine which DNA substrate it binds; the specific sequence of Ecm16’s
insertion domain is involved in substrate-dependent ATPase activity. Taken together, our results
propose a two-step DNA damage detection model. In the first step, Ecm16 discriminates damaged
DNA from normal DNA by differential DNA binding affinity. Ecm16 binds substantially more
strongly to echinomycin- and doxorubicin-containing DNA compared to normal DNA. This initial
screening step requires the insertion domain, as indicated by the observation that Ecm16ΔID
displays a similar weak binding affinity toward damaged and normal DNA. In the second step,
Ecm16-bound DNA substrates are further discriminated by their ability to stimulate the ATPase
activity of Ecm16. DNA-echinomycin drastically increases Ecm16’s ATP hydrolysis rate but
DNA-doxorubicin does not. This second step also requires the insertion domain, as DNAechinomycin does not stimulate the ATPase activity of Ecm16*.
Our data revealed the striking differences in the regulation of the ATPase activity between
Ecm16 and UvrA. We showed that Ecm16 regulates its ATPase activity based on the type of
substrate (damaged vs. undamaged DNA), and we identified the essential role that the insertion
domain plays in this regulation. Unlike, Ecm16, the ATPase activity of UvrA was previously
reported to remain the same with damaged and undamaged DNA.89 Our data with UvrA confirmed
these previous findings. Furthermore, in the presence of DNA-echinomycin, the ATPase activity
of Ecm16 is seven-fold higher than the maximum ATPase activity of UvrA. One possible
explanation to the difference in regulation and/or activity is that Ecm16, unlike UvrA, carries out
its activity without the assistance from the other components of the NER system. Even within the
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first step of repair, UvrB has been proposed to assist UvrA in the detection and confirmation of
DNA damage.122 Ecm16 could potentially use its ATPase activity to perform additional functions
in DNA repair that go beyond the detection of damaged DNA. If this is the case, Ecm16 may be
using a novel mechanism for DNA repair that will add to the repertoire of DNA repair mechanisms
that are currently known. In sum, our accumulative data unveiled interesting mechanistic
differences between class I and class II UvrA proteins that further explain the differences in their
function. Our study has demonstrated that Ecm16 provides echinomycin resistance to the host cell.
This is the first confirmed unique function of a class II UvrA protein. However, more work is
needed to fully understand how Ecm16 renders echinomycin resistance.
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Glossary
Table 8.1: List of strains, plasmids and primers used in this study.
Strain #

Description

Genotype

Source

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBJW4019-2

K12_∆uvrA

3), λ, rph-1, Δ(rhaD-

110

rhaB)568, ΔuvrA753::kan, hsdR514
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBJW0762-2

K12_∆uvrB

3), λ, ΔuvrB751::kan, rph-1, Δ(rhaD-

110

rhaB)568, hsdR514
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBJW1898-1

K12_∆uvrC

3), λ, ΔuvrC759::kan, rph-1, Δ(rhaD-

110

rhaB)568, hsdR514
BW25113

K12 parental strain F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBfrom Keio collection

110,132

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514

Keio K12 parental F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM440

strain/pBAD-Myc-

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514

HisA

/ pBAD-Myc-HisA

This study

Keio K12 parental F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM441

strain/pBAD-Myc-

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514

HisA-ecm16

/ pBAD-Myc-HisA-ecm16

This study

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM442

K12_∆uvrA/pBAD-

3), λ, rph-1, Δ(rhaD-

Myc-HisA

rhaB)568, ΔuvrA753::kan, hsdR514

This study

/pBAD-Myc-HisA
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM443

K12_∆uvrA/pBAD-

3), λ, rph-1, Δ(rhaD-

Myc-HisA-ecm16

rhaB)568, ΔuvrA753::kan, hsdR514
/ pBAD-Myc-HisA-ecm16
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This study

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM444

K12_∆uvrB/pBAD-

3), λ, ΔuvrB751::kan, rph-1, Δ(rhaD-

Myc-HisA

rhaB)568, hsdR514

This study

/ pBAD-Myc-HisA
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM445

K12_∆uvrB/pBAD-

3), λ, ΔuvrB751::kan, rph-1, Δ(rhaD-

Myc-HisA-ecm16

rhaB)568, hsdR514

This study

/ pBAD-Myc-HisA-ecm16
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM446

K12_∆uvrC/pBAD-

3), λ, ΔuvrC759::kan, rph-1, Δ(rhaD-

Myc-HisA

rhaB)568, hsdR514

This study

/ pBAD-Myc-HisA
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM447

K12_∆uvrC/pBAD-

3), λ, ΔuvrC759::kan, rph-1, Δ(rhaD-

Myc-HisA-ecm16

rhaB)568, hsdR514

This study

/pBAD-Myc-HisA-ecm16
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM483

K12_∆uvrA/pBAD-

3), λ, rph-1, Δ(rhaD-

uvrA

rhaB)568, ΔuvrA753::kan, hsdR514

This study

/ pBAD-uvrA

PM489

Keio K12 parental
strain/pBAD-uvrA

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/ pBAD- This study
uvrA

Keio K12 parental F-, Δ(araD-araB)567, ΔlacZ4787(::rrnBPM518

strain/pBAD-ecm16-

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/ pBAD- This study

K56A

ecm16-K56A

Keio K12 parental F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ,
PM519

strain/pBAD-ecm16-

rph-1, Δ(rhaD-rhaB)568, hsdR514/

K526A

ecm16-K526A
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pBAD- This study

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λJW3786-5

K12_∆uvrD

, rph-1, ΔuvrD769::kan, Δ(rhaD-

110

rhaB)568, hsdR514

PM535

PM536

PM601

K12_∆uvrD / pBADMyc-HisA
K12_∆uvrD / pBADMyc-HisA-ecm16

K12/pBAD-MycHisA-ecm16∆ID

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ, rph-1, ΔuvrD769::kan, Δ(rhaD-

This study

rhaB)568, hsdR514/ pBAD-Myc-HisA
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ, rph-1, ΔuvrD769::kan, Δ(rhaD-

This study

rhaB)568, hsdR514/pBAD-Myc-HisA-ecm16
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/ pBAD- This study
Myc-HisA-ecm16
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-

PM603

K12/pBAD-Myc-

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/pBAD-

HisA-ecm16-E708Q

Myc-HisA-ecm16/

pBAD-Myc-HisA-ecm16-

This study

E708Q
K12/pBAD-MycPM604

HisA-ecm16-E399QE708Q

PM619

K12/pBAD-MycHisA-ecm16*

F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/pBADMyc-HisA-ecm16/

pBAD-Myc-HisA-ecm16-

This study

E399Q-E708Q
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/pBAD-

This study

Myc-HisA-ecm16/ pBAD-Myc-HisA-ecm16*
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-

PM676

K12/pBAD-Myc-

3), λ, rph-1, Δ(rhaD-rhaB)568, hsdR514/pBAD-

HisA-ecm16-E399Q

Myc-HisA-ecm16/

pBAD-Myc-HisA-ecm16-

This study

E399Q
Thermo

Plasmids

pDNA220

Fisher
Thermo

pBAD-Myc-HisA

Fisher
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pDNA223
pDNA224

pDNA247

pDNA236

pDNA237

pDNA238

pDNA239

pDNA313

pDNA267

pDNA268

pET28a-ecm16

This study

pBAD-Myc-HisA-

This study

uvrA
pBAD-Myc-HisA-

This study

ecm16
pET28a-ecm16-

This study

K56A
pET28a-ecm16-

This study

K526A
pBAD-Myc-HisA-

This study

ecm16-K56A
pBAD-Myc-HisA-

This study

ecm16-K526A
pET28a-ecm16-

This study

E399Q
pET28a-ecm16-

This study

E708Q
pET28a-ecm16-

This study

E399Q, E708Q

pDNA269

pET28a-ecm16ΔID

This study

pDNA281

pET28a-ecm16*

This study

pDNA245

pET28a-UvrA

pDNA314

pDNA284

This
study

pBAD-Myc-HisA-

This

ecm16-E399Q

study

pBAD-Myc-HisA-

This

ecm16-E708Q

study
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pBAD-Myc-HisApDNA286

This

ecm16-E399Q-

study

E708Q
pDNA288

pDNA285

pBAD-Myc-HisA-

This

ecm16*

study

pBAD-Myc-HisA-

This

ecm16∆ID

study

Genes
Ecm16-5'-SacI-fow

AAAGAGCTCCATATGACCGCGGGTACC

Ecm16-3'-EcoRI-rev

AAAGAATTCTTACGCGCCCACATACTGCG

Ecm16 NdeI-fow

AAACATATGACCGCGGGTACCGAAACCGATACCCAGC

Ecm16 EcoRI-rev

AAAGAATTCTTACGCGCCCACATACTGCGCCAGGT

Ecm16-BamHI-fow

AAAAATCGCGGATCCATGACCGCGGGTACCGAA A

Ecm16-XbaI-rev

AAACGACTAGTCTAGATTACGCGCCCACATACTGCGCC

Ecm16K56A-fow

TAGCGGCGCAAGCAGCCTGGTGTTTGACACCAT

Ecm16K56A-rev

ACCAGGCTGCTTGCGCCGCTACCGCT

Ecm16K526A-fow

GGTAGCGGTGCAAGCAGCCTGATTCACGGTAGCGTT

Ecm16K526A-rev

AATCAGGCTGCTTGCACCGCTACCCGCCA

UvrA-SacI-fow

GAGCTCATGGATAAGATCGAAGTTC

UvrA-HindIII-rev

AAGCTTTTACAGCATCGGCTTAAG

Ecm16E399Q-rev

AGGCCCACGGTCGGTTCATCAAACA

Ecm16E708Q-fow

GCGTTTATATCCTGGATCAACCGACCA

Sequencing
T7 promoter

TAATACGACTCACTATAGG

T7 terminator

GCTAGTTATTGCTCAGCG

pBAD sequencing primer 1-fow133

CTGTTTCTCCATACCCGTT

pBAD sequencing primer 2 -rev133

GGCTGAAAATCTTCTCT

pBAD-fow-INVITROGEN

ATGCCATAGCATTTTTATCC

pBAD-rev-INVITROGEN

GATTTAATCTGTATCAGG

5'-Mid_ecm16_fow

TAACACCACCTATGAAGGCCTGC
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3'-Mid-ecm16-rev

GGTCCACGGTAACCACACCA

Gibson
TGGCGCAGTATGTGGGCGCGTAATAAGGAAGAGCGCT
Gib_ecm16-pCV3-down-fow

CTTCG
CTTTTACGAAGAGCGCTCTTCCTTATTACGCGCCCACA

Gib_ecm16-down-rev

TACTGC
TTTGGAGGAGGGCTAGCGAATTCATGACCGCGGGTAC

Gib_ecm16-up-fow

CGA
TCGGTTTCGGTACCCGCGGTCATGAATTCGCTAGCCCT

Gib_ecm16-pCV3-up-rev

CC
CCCCGAACTTCGATCTTATCCATGAATTCCTCCTGCTAG

Gib_uvrA-pCV1-up-rev

C
GCACGCTTCCTTAAGCCGATGCTGTAATAAGGAAGAGC

Gib_uvrA-pCV1-down-fow

GCTCTTCG
TTTACGAAGAGCGCTCTTCCTTATTACAGCATCGGCTT

Gib_uvrA-pCV1-down-rev

AA
TTTTGGGCTAGCAGGAGGAATTCATGGATAAGATCGA

Gib_uvrA-pCV1-up-fow

AGT
AGTTTTTGTTCGGGCCCAAGCTTTTACAGCATCGGCTT

Gib_uvrA-pBad-down-rev

AA
GAATTAACCATGGATCCGAGCTCATGGATAAGATCGA

Gib_uvrA-pBad-up-fow

AGT
CCCCGAACTTCGATCTTATCCATGAGCTCGGATCCATG

Gib_uvrA-pBad-up-rev

GT
GCTTCCTTAAGCCGATGCTGTAAAAGCTTGGGCCCGAA

Gib_uvrA-pBad-down-fow

CA
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Table 8.2: Sequence of DNA substrates used in this study.98,134,135 Drug-binding and base
modification sites are underlined.
5’-AGTGATCAGTGGTTACGTAACCACTGATCACT-3’
DNA-echinomycin
3’-TCACTAGTCACCAATGCATTGGTGACTAGTGA-5’
5’-AGTGATCAGTGGTXCCGGAACCACTGATCACT-3’
DNA-fluorescein
3’-TCACTAGTCACCAAGGCCXTGGTGACTAGTGA-5’
5’-AGTGATCAGTGGTTACGTAACCACTGATCACT-3’
DNA-doxorubicin
3’-TCACTAGTCACCAATGCATTGGTGACTAGTGA-5’

Table 8.3: Sequence identity matrix for select class I and II UvrA proteins calculated using
ClustalW92
Protein

1

2

3

4

5

6

7

8

9

10

1. Ecm16 (S. lasalocidi)

100.0

64.2

51.2

37.2

38.8

39.8

42.1

41.0

39.4

39.1

2. SnorO (S. nogalator)

64.2

100.0

53.6

39.9

39.7

39.4

44.4

42.1

39.5

41.2

3. DrrC (S. peuceticus)

51.2

53.6

100.0

39.6

41.5

39.5

45.1

44.6

42.5

42.2

4. UvrA2 (X. axonopodis)

39.8

39.4

39.5

67.6

69.1

100.0

44.6

47.9

41.8

42.5

5. UvrA2 (D. radiodurans)

38.8

39.7

41.5

66.3

100.0

69.1

47.5

48.6

43.5

46.7

6. UvrA2 (P. Putida)

37.2

39.9

39.6

100.0

66.3

67.6

44.6

48.0

42.3

46.2

7. UvrA (B. Stearothermophilus)

39.1

41.2

42.2

46.2

46.7

42.5

59.7

59.8

62.1

100.0

8. UvrA (E. coli)

39.4

39.5

42.5

42.3

43.5

41.8

55.4

56.7

100.0

62.1

9. UvrA (M. tuberculosis)

40.9

42.1

44.6

48.0

48.6

47.9

56.4

100.0

56.7

59.8

10. UvrA (T. maritima)

42.1

44.4

45.1

44.6

47.5

44.6

100.0

56.4

55.4

59.7
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